VR-2332 VIRAL NUCLEOTIDE SEQUENCE AND METHODS OF USE

Abstract: A nucleotide sequence is provided for the VR-2332 virus, which is capable of causing Porcine Reproductive and Respiratory Syndrome. The nucleotide sequence includes protein coding regions that are inserted into recombinant vectors for the host expression of viral proteins according to a variety of vaccination techniques. Diagnostic assays utilize fragmentary sequences or oligonucleotides to selectively identify the VR-2332 nucleic acids by hybridization or PCR amplification reactions that distinguish VR-2332 nucleotide sequences from other PRRS-causative viruses which are immunologically distinct from VR-2332.

Description: VR-2332 VIRAL NUCLEOTIDE SEQUENCE AND METHODS OF USE Sequence Listing A printed Sequence Listing accompanies this application, and is also submitted with identical contents in the form of a computer-readable ASCII file. Background of the Invention 1. Field of the Invention The invention pertains to the field of molecular genetics and, in particular, to the use of man-made nucleotides in diagnosing animal diseases or vaccinating animals against disease. More specifically, the preferred nucleotides derive from an immunologically distinct strain of the porcine reproductive and respiratory syndrome ("PRRS") virus, and selectively target this virus in the application of vaccination or diagnostic techniques. 2. Description of the Prior Art A new viral disease of pigs was detected in North America during 1987, and reported by Hill, Overview and History of Mystery Swine Disease (Swine Infertility and Respiratory syndrome), in Proceedings of the Mystery Swine Disease Committee Meeting, October 6, Denver CO, from the Livestock Conservation Institute of Madison, Wisconsin pp. 29-30 (1990). A disease having substantially identical clinical signs was found in Europe during 1990, as reported by Paton et al., Blue ear disease of pigs, 128 Vet Rec. 617 (1991). The clinically observed disease is commonly known by various names including porcine reproductive and respiratory syndrome ("PRRS"), swine infertility and respiratory syndrome ("SIRS"), porcine epidemic abortion and respiratory syndrome ("PEARS"), and mystery swine disease; herein, the term PRRS will suffice to indicate all of these names. The consequences of this disease included late-term abortions and stillbirths in sows, as well as respiratory insufficiencies in nursery pigs that developed poorly and died easily. Decreases were observed in sow conception rates and litter sizes. Estimates stated that about ten to fifteen percent of pig production were lost annually due to reproductive failure. Early clinical signs of the disease included anorexia and mild pyrexia. Other signs included bluish discolorations on the skin of diseased herd animals, with the discolorations being primarily located on the ears, teats, snout, and frontal portions of the neck and shoulders. Necropsy results indicated thickened alveolar septae caused by the presence of macrophages, degenerating cells, and debris in alveolar spaces. These abnormalities indicated the presence of PRRS virus. The causative viral agent was suspected to be a small, enveloped positive-stranded RNA virus that was recovered primarily from alveolar macrophages of infected swine, as reported by Benfield et al., Characterization of swine infertility and respiratory syndrome (SIRS) virus (isolate ATCC VR-2332), 4 J. Vet. Diagn. Invest. 127-133 (1992); and Wensvoort et al., Leiystad virus, the cause of porcine epidemic abortion and respiratory syndrome: a review of mystery swine disease research at Leiystad, 33 Vet. Micro. 185-193 (1992). The isolation technique for the Leiystad ("LV) virus included homogenizing infected swine lung tissue; mixing the homogenate with a physiological saline, e.g., Ringers solution, Hank's balanced salt solution, and Minimum Essential Medium ("MEM") to a 10% weight/volume amount of the homogenate; and filtering the mixture through a series of 0.45, 0.2 and 0.1 micron filters. The LV virus appeared to be closely related to arteriviruses in morphology, genome organization, transcriptional regulation, and macrophage specificity, according to Plagemann et al., Lactate dehydrogenase-elevating virus, equine arteritis virus and simian hemorrhagic fever virus: a new group of positive-strand RNA viruses, 41 Adv. Vir. Res. 99-192 (1992). The complete nucleotide sequence of the LV strain of the PRRS virus was identified by Meuienberg et al., Leiystad virus, the causative agent of porcine epidemic abortion and respiratory syndrome (PEARS), is related to LDV and EAV, 192 Virology 62-72 (1993). A partial LV sequence was also identified by Conzelmann et al., Molecular characterization of porcine reproductive and respiratory syndrome virus, a member of the arterivirus group, 193 Virology 193, 329-339. The positives-strand genome of the LV virus (Sequence ID. Nos. 14-26) included eight open reading frames ("ORFs"), which had some similarity in comparison with the genes of coronaviruses and arteriviruses. Two open reading frames likely coded for the viral RNA polymerase. LV ORFs two through six appeared to code for structural proteins associated with viral membranes, and LV ORF 7 was believed to code for a nucleocapsid. The LV viral proteins were expressed from a nested set of RNA transcripts that had overlapping 3' ends. While this expression strategy was shared with the Coronavirus family, the physical properties of the LV virus originally placed it in the Togavirus family. Plagemann et al. (see above) has proposed a new family, the Arteriviridae, to encompass viruses having these dual properties. This family included the PRRS virus, equine arteritis virus ("EAV), lactate dehydrogenase-elevating virus ("LDV), and simian hemorrhagic fever virus ("SHFV). A second strain ("VR-2332") of the PRRS virus was isolated as a fourth cell culture passage, as reported by Benfield et al., Characterization of swine infertility and respiratory syndrome (SIRS) virus (isolate ATCC VR-2332), 4 J. Vet. Diagn. Invest. 4, 127-133 (1992). Nevertheless, the viral genome was not sequenced. The VR-2332 isolate was deposited in the American Type Culture Collection, and now has an ATCC catalogue number VR-2332. The VR-2332 virus was characterized as spherical with an average diameter of 62 nm and a 25-30 nm core surrounded by an envelope. Viral particles had a buoyant density of 1.18-1.19 g/ml in cesium chloride and were further purified from filtered tissue homogenates by centrifugation on cesium chloride gradients. The respective VR-2332 and LV virus isolates displayed vast differences in terms of antigenic variation, especially in view of their common morphology and similar clinical signs in swine. A comparison study between 24 field sera and seven viral isolates from Europe and North America failed to distinguish a single common antigen which was able to diagnose infection in a reliable manner for both viruses, as reported by Wensvoort et al., Antigenic comparison of Leiystad virus and swine infertility and respiratory syndrome (SIRS) virus, 4 J. Vet. Diagn. Invest. 134-138 (1992). Accordingly, despite the structural and symptomological similarities between the two virus strains, it is unlikely that a single vaccine could be developed from one strain of the virus for puφoses of immunizing swine against both strains. Summary of the Invention The present invention overcomes the problems that are outlined above by providing man-made nucleotide sequences for the immunologically distinct VR-2332 strain of PRRS virus, as well as vaccines derived from these nucleotides and corresponding methods of vaccination. Broadly speaking, the present invention includes materials and methods that derive from the VR-2332 form of PRRS pathogen. The materials preferably include VR-2332 virus based nucleic acids and proteins having lengths sufficient to make them unique in comparison with the LV form of PRRS pathogen. The methods involve the use of these materials in diagnostic assays and vaccination procedures. A particularly preferred material of the present invention includes a purified and isolated nucleic acid coding for a fragmentary portion of the VR- 2332 genomic sequence between ORF 2 and ORF 7. These sequences are unique with respect to the LV virus genome, and preferably code for the expression of a polypeptide capable of inducing an anti-VR-2332 PRRS immune response in swine. Despite the similarity in PRRS clinical signs and viral morphology between the VR-2332 and LV viruses, VR-2332 based oligonucleotides can be used as polymerase chain reaction ("PCR") primers for the selective amplification of VR-2332 cDNA. These sequences also include inverse complimentary oligonucleotide sequences derived from the VR-2332 genome. These oligonucleotide sequences are also capable of being used as probes in hybridization studies to selectively identify wild-type VR-2332 cDNA. Portions of the VR-2332 nucleotide sequence may be recombined with a chimeric vector to place the VR-2332 coding region insert under the control of an appropriate promoter sequence and a termination sequence. This vector may be used for host expression of a protein coded for by the insert. Host expression may be accomplished in either prokaryotic or eukaryotic cells. These vectors may be constructed as recombinant plasmids and injected directly into swine to induce an immune response as the host-swine produces viral proteins. Altematively, the viral proteins may be produced in cell cultures and injected into swine for immunization purposes. These nucleotide sequences may also be used in PCR diagnostic assays utilizing primers that selectively amplify either VR-2332-based cDNA or LV-based cDNA. Alternatively, these primer sequences can be used in hybridization reactions that indicate the presence of a particular PRRS- causative virus. Other objects, advantages and salient features of the present invention will become apparent from the following detailed description which, when taken into conjunction with the annexed drawings, discloses a number of embodiments of the present invention. Brief Description of the Drawings Figure 1 depicts the positional organization of VR-2332 ORFs 2 through 7 with reference to shaded regions corresponding to cDNA fragments from various clones that were used to determine the nucleotide sequence of the VR-2332 strain of the PRRS virus to yield Sequence ID No. 1 ; Fig. 2 depicts the nucleotide and deduced amino acid sequence of VR-2332 ORFs 2 through 7, which correspond to Sequence ID Nos. 1 through 13; Fig. 3A depicts a comparison between the respective amino acid alignments of ORF 7 for VR-2332 and LV virus according to an IUPAC single letter amino acid code wherein identical residues are represented by capital letters and different residues are represented by lower case letters, and the full three letter amino acid code sequences for these residues are provided in Sequence ID No. 13 (VR-2332) and Sequence ID. No. 26 (LV virus); Fig. 3B depicts a hydropathy profile for VR-2332 ORF 7, wherein the ordinate represents a hydrophobicity value and the abscissa represents a residue number; Fig. 3C depicts a hydropathy profile for LV virus ORF 7, which is substantially similar to Fig. 3B; Fig. 4A depicts a comparison between the respective amino acid alignments of ORF 6 for VR-2332 and LV virus according to an IUPAC single letter amino acid code wherein identical residues are represented by capital letters and different residues are represented by lower case letters, and the full three letter amino acid code sequences for these residues are provided in Sequence ID No. 11 (VR-2332) and Sequence ID. No. 24 (LV virus); Fig. 4B depicts a hydropathy profile for VR-2332 ORF 6, wherein the ordinate represents a hydrophobicity value and the abscissa represents a residue number; Fig. 4C depicts a hydropathy profile for LV virus ORF 6, which is substantially similar to Fig. 4B; Fig. 5A depicts a comparison between the respective amino acid alignments of ORF 5 for VR-2332 and LV virus according to an IUPAC single letter amino acid code wherein identical residues are represented by capital letters and different residues are represented by lower case letters, and the full three letter amino acid code sequences for these residues are provided in Sequence ID No. 9 (VR-2332) and Sequence ID. No. 22 (LV virus); Fig. 5B depicts a hydropathy profile for VR-2332 ORF 5, wherein the ordinate represents a hydrophobicity value and the abscissa represents a residue number; Fig. 5C depicts a hydropathy profile for LV virus ORF 5, which is substantially similar to Fig. 5B; Fig. 6A depicts a comparison between the respective amino acid alignments of ORF 4 for VR-2332 and LV virus according to an IUPAC single letter amino acid code wherein identical residues are represented by capital letters and different residues are represented by lower case letters, and the full three letter amino acid code sequences for these residues are provided in Sequence ID No. 7 (VR-2332) and Sequence ID. No. 20 (LV virus); Fig. 6B depicts a hydropathy profile for VR-2332 ORF 4, wherein the ordinate represents a hydrophobicity value and the abscissa represents a residue number; Fig. 6C depicts a hydropathy profile for LV virus ORF 4, which is substantially similar to Fig. 6B; Fig. 7A depicts a comparison between the respective amino acid alignments of ORF 3 for VR-2332 and LV virus according to an IUPAC single letter amino acid code wherein identical residues are represented by capital letters and different residues are represented by lower case letters, and the full three letter amino acid code sequences for these residues are provided in Sequence ID No. 5 (VR-2332) and Sequence ID. No. 18 (LV virus); Fig. 7B depicts a hydropathy profile for VR-2332 ORF 3, wherein the ordinate represents a hydrophobicity value and the abscissa represents a residue number; Fig. 7C depicts a hydropathy profile for LV virus ORF 3, which is substantially similar to Fig. 7B; Fig. 8A depicts a comparison between the respective amino acid alignments of ORF 2 for VR-2332 and LV virus according to an IUPAC single letter amino acid code wherein identical residues are represented by capital letters and different residues are represented by lower case letters, and the full three letter amino acid code sequences for these residues are provided in Sequence ID No. 3 (VR-2332) and Sequence ID. No. 16 (LV virus); Fig. 8B depicts a hydropathy profile for VR-2332 ORF 2, wherein the ordinate represents a hydrophobicity value and the abscissa represents a residue number; Fig. 8C depicts a hydropathy profile for LV virus ORF 2, which is substantially similar to Fig. 8B; and Fig. 9 depicts a comparison between the respective 3' untranslated regions of VR-2332 and LV virus. Detailed Description of the Preferred Embodiment The following non-limiting Examples set forth preferred methods and materials for practicing the present invention. EXAMPLE 1 GROWTH OF THE VR-2332 VIRUS A virally pure MA-104 cell line culture of the ATCC VR-2332 virus was obtained for use as viral inoculum, courtesy of Boehringer Ingelheim of Ridgefield, Connecticut. A culture was prepared for use in propagating the VR-2332 inoculum. The VR-2332 virus was grown in cells from a monkey kidney cell line according to the methods outlined by Gravell et al., 181 Proc. Soc. Exp. Biol. Med., 112-119. Those skilled in the art may altematively refer to the cell line as the 2621 , MA-104 or USU-104 cell line. Uninfected cells were cultured in 50 ml of Eagle's MEM medium (purchased from Life Technologies, Inc., Gaithersburg, MD), which was supplemented with 10% fetal calf serum and 50 μg/ml gentamicin from Sigma Chemical Co. of St. Louis, MO. Cells were dislodged from the flask surface with trypsin-versene, centrifuged to pellet the cells for separation from the trypsin-versene supernatant, and split 1 :4 for subculturing. The cells were maintained in a 5% humidified CO 2 atmosphere at 37 °C in 75 cm 2 plastic tissue culture flasks, with media passage at 5-7 day intervals. The four 50 ml cell cultures were each infected by decanting the growth media and adding the VR-2332 inoculum in 1 ml of growth media having a titer of approximately 10 s -10 6 tissue culture infective doses (TCID 50 ). The resultant mixture was incubated for 30 min, after which time was added 30 ml of fresh MEM media containing 4% fetal calf serum. The infected cells were incubated under CO 2 as described above for 24 or 48 hr, and harvested by decanting the media to leave cells adhered to the flask walls. EXAMPLE 2 CONSTRUCTION OF A cDNA LIBRARY The harvested cells from Example 1 were washed with phosphate-buffered saline, and lysed by the addition of 5M guanidine iso- thiocyanate. Total cellular RNA was extracted according to the protocols described by Chomczynski et al., Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction, 162 Anal. Biochem. 156-159 (1987). Poly A-containing RNA was selected by oligo dT column chromatography using conventional equipment and procedures from Gibco BRL of Gaithersburg, MD. A cDNA library was constructed in the lambda unidirectional phage vector, UniZap™XR, using Gigapack ® II Gold 1 packaging extract and E. coli SURE™ cells, as directed by the kit manufacturer (Stratagene, La Jolla, CA). This procedure is summarized below with reference to materials provided in the commercially available kit. The poly A-selected RNA obtained from 2 ml of cell lysate was reverse transcribed with Moloney murine leukemia virus reverse transcriptase and a synthetic 50 base oligo dT primer containing a sequence including an Xho I restriction site, as follows: 5'-GAGAGAGAGAGAGAGAGAGAACTAGTCTCGAG I I I I I I I I I I I I I I I I TT-3\ ^niZap XR, Gigapack II Gold, and SURE are trademarks of Stratagene Corp. of La Jolla, CA. The first strand synthesis reaction also contained 5-methyl dCTP. Second strand synthesis was achieved by utilizing DNA polymerase I and the standard dCTP instead of 5-methyl dCTP. The ends of the double stranded cDNA were made blunt with T4 DNA polymerase, and EcoRI adaptors were added with T4 DNA ligase. The adaptors had the following synthetic nucleotide sequences: S'-AATTCGGCACGAG-S' 3'-GCCGTGCTC-5' The resulting cDNA was treated with polynucleotide kinase to phosphorylate the 5' ends, digested to completion with Xho I, and purified on a Sephacryl S-400 column. The cDNA was ligated to the Uni-ZAP™ XR vector arms with DNA ligase and packaged in the high efficiency packaging extract, Gigapack ® II Gold. The resulting packaged infectious phage preparation was plated on the E. coli cell line SURE™. EXAMPLE 3 SCREENING THE cDNA LIBRARY BY PCR Many unsuccessful attempts were made to screen the cDNA library of Example 2 for purposes of identifying VR-2332 positive plaques by polymerase chain reaction using PCR primer sequences derived from the reported LV virus. Synthetic DNA fragments or primers were produced and labeled with 32 P as an indicator according to conventional protocols. These oligonucleotide primers replicated portions of LV virus ORFs 2, 6 and 7, as were reported by Meuienberg et al., Leiystad virus, the causative agent of porcine epidemic abortion and respiratory syndrome (PEARS), is related to LDV and EAV, 192 Virology 62-72 (1993). No PCR amplified nucleotide products were obtained under a variety of conditions. The observed total failure in PCR amplification of VR-2332 nucleic acid sequences indicated that the two viruses (LV and VR-2332) have considerable nucleotide sequence differences, which are sufficient to prevent specific PCR amplification of VR-2332 cDNA using LV-derived primers. Therefore, an alternative cloning strategy was devised using LV sequences for hybridization, but not for PCR, to determine the nucleotide sequence corresponding to the structural genes of the VR-2332 strain of the PRRS virus. EXAMPLE 4 SCREENING THE cDNA LIBRARY BY PLAQUE HYBRIDIZATION A PCR-generated nucleotide fragment that replicated cDNA from LV ORF 7 (Sequence ID No. 26 of the LV virus) was 32 P-labeled, and used to probe Northern blots obtained using MA-104 cells infected with the VR-2332 virus. Radiographic bands were obtained from infected cells, but not from uninfected cells. These bands indicated that LV and VR-2332 shared similar sequences which were capable of hybridizing despite the failure of PCR screening in Example 3. Several fifteen cm agar plates containing a total of about 50,000 plaques were screened from duplicate lifts onto NitroPlus nitrocellulose membranes (Micron Separations Inc., Westboro, MA). Positive plaques that hybridized to the corresponding LV virus probe were identified by their corresponding radiographic bands as determined by exposure to x-ray film. These positive plaques were replated and rescreened for confirmation. Hybridization-positive recombinant Uni-ZAP™ XR phage were subjected to in vivo excision as described in the Stratagene instruction manual, in order to obtain plasmid DNA for sequence analysis. A summary of the Stratagene procedure is set forth below. Recombinant phage were combined with E. coli XL1-Blue cells as well as ExAssist helper phage at 37°C for 15 min and, thereafter, cultured in rich media for 2-3 hours with shaking at 37°C. The culture was heated to 70°C for 20 min, and clarified by centrifugation. Supernatant containing rescued phagemid was added to SOLR cells and plated on ampi- cillin-containing agar plates. These bacterial colonies contained recombinant plasmids. The resultant clones were amplified in liquid culture. DNA was extracted and further analyzed by EcoRI and Xhol restriction endonuclease digestion (10X excess). The sizes of the VR-2332-specifιc inserts were estimated by electrophoresis in agarose gels with molecular weight standards. Next, the nucleotide sequence of 23 clones was determined at the 3' end by dideoxynucleotide sequencing using Sequenase, 35 S-dATP and Stratagene's synthetic M13 -20 primer: 5'-GTAAAACGACGGCCAGT-3' . Sequencing products were analyzed on 6% denaturing polyacrylamide gels. Twenty of 23 clones had identical 3' sequences, suggesting these clones were coterminally nested. Six of these 20 clones of various sizes, all containing an identical 3' end, were selected for further DNA sequencing. EXAMPLE 5 VR-2332 SEQUENCE ANALYSIS Nucleotide sequence data were obtained for each of the six selected clones of Example 4 by manual dideoxynucleotide sequencing with Sequenase (US Biochemicals, Cleveland, OH) and automated fluorescence sequencing (Applied Biosystems, Foster City, CA). Fig. 1 schematically depicts the native positions of the six clones, i.e., those designated 761, 712, 431 , 412, 513, and 416, which were chosen for further sequence analysis. The fragment length scale proceeds from 0 to about 3.5 kb, with a positional reference to Sequence ID No. 1. Clones 431 , 412, 513 and 416 were sequenced from their 5' ends to overlap with the sequence generated from the next smaller clone. The gap between the 5' end of clone 416 and the beginning of ORF 2, which was sequenced from both clones 712 and 761 , was sequenced from both ends by synthesizing VR-2332-specific primers. Additional sequencing was performed to confirm the sequence on the opposite strand. This strategy produced a sequence of 3358 nucleotides, i.e., Sequence ID. No. 1, on both strands from a combination of six independent clones. Fig. 2 depicts this total sequence, together with its deduced amino acid translation. Numerous differences between the LV and VR-2332 viruses occurred throughout the 3' genomic sequences that coded for ORFs 2 through 7, as well as the 3' untranslated region. These differences were due to nucleotide substitutions, base deletions and base additions. The sequence divergence arose, presumably, from error-prone replication, and suggests that the viral replicase has poor fidelity and lacks proofreading activity. EXAMPLE 6 AMINO ACID RESIDUE SEQUENCE COMPARISON AND IMMUNOLOGICAL CROSS-REACTIVITY An initial survey indicated that the deduced proteins from these six VR-2332 ORFs roughly corresponded to known ORFs 2 through 7 in each of LV virus, LDV, and EAV. Accordingly, a detailed comparative study was performed to determine differences between the amino acid residue sequences of the VR-2332 and the LV virus, as well as the other Arteriviridae including LDV and EAV. The amino acid sequence comparison was performed using GCG (University of Wisconsin, Madison, Wl) and Intelligenetics, Inc. (Mountain View, CA) software. Sequence ID No. 1 includes the VR-2332 sequence for the 3-most 3442 bases of the VR-2332 nucleotide sequence, as well as the 5'- most 84 bases preceding the start of ORF 2. These 3358 nucleotides encode the structural proteins of the virus, and include six ORFs with each ORF corresponding to Sequence ID Nos.2-13. These VR-2332 ORFs have varying degrees of homologies in comparison with LV ORFs 2-7 as well as other members of the Arteriviridae family including LV virus, LDV, and EAV. More specifically, a comparative sequence analysis indicates a degree of amino acid sequence homology between the VR-2332 virus and the LV virus ranging from 55% in ORF 5 to 79% in ORF 6. Table 1 provides the results of this Arteri¬ viridae family comparison. Table 1 Percent Amino Acid Identity of VR-2332 with LV LDV and EAV* 'Homologies were determined using the Needleman-Wunsch algorithm to align sequences and dividing the number of identical amino acids by the total number of amino acids in the smaller ORF. Since ORF 3 of LDV and EAV is significantly smaller than VR-2332 ORF 3, the homology based on division by VR-2332 is also shown in parentheses. While the VR-2332 ORFs were most like those of LV virus, the comparison of VR-2332 to LDV indicated that VR-2332 has shared an evolutionary history with LDV. VR-2332 shared 55% identity with ORF 5 of LV virus, but had the lowest overall degree of homology with LV. The VR-2332 ORF 5 had the greatest degree of overall homology with respect to its LDV counterpart. VR-2332 ORF 5, which had about 52% identity with LDV ORF 5, was only slightly more similar to LV than it was to LDV. When VR-2332 was compared to LDV, the homologies were higher in ORFs 5, 6, and 7 than in ORFs 2, 3, and 4. Other than providing a basis for explaining the observed antigenic variance between these related viruses, the further significance of these divergences is unclear, in part because the functions of proteins derived from ORFs 2, 3, and 4 are unknown. These amino acid sequence analyses also demonstrated that, with few exceptions, the sequence differences were widely distributed. The principal differences were located in the signal-sequence coding 5' ends of the ORFs, and ORF 4 in the region of amino acid residues 50-70. Both VR-2332 and the LV virus have been identified as different infectious agents that cause the PRRS clinical signs, but have demonstrated very little, if any, immunological cross-reactivity, as reported by Wensvoort et al. (see above). Nevertheless, the deduced amino acid sequence from the 3' end of VR-2332 (Sequence ID Nos. 3, 5, 7, 9, 11, and 13) revealed a genomic organization that is characteristic of the Arteriviridae, i.e., overlapping coding regions in different reading frames of Sequence ID No. 1. A dot-matrix analysis was performed by utilizing the GCG software to compare the predicted protein structures for ORFs 2-7 of VR-2332 and the LV virus. As will be understood by those skilled in the art, the dot matrix analysis was performed according to a conventional technique by utilizing a sliding window of 21 amino acids with a requirement of 13 identical residues at each location. This analysis demonstrated that all of the ORFs were substantially collinear between VR-2332 and LV, i.e., the respective viral structures were very similar despite extensive amino acid diversity. The nearly collinear nature of the VR-2332 and LV ORFs also indicated that the amino acid residue differences did not arise from genomic rearrangements. Table 2 provides a detailed comparison of the various deduced amino acid residues that correspond to the respective ORFs in VR-2332 and LV virus. Table 2 Comparison of VR-2332 and LV Virus ORFs 2-7 Glycosylation ORF Amino Acids Predic ed KD pl Sites 2332 LV 2332 LV 2332 LV 2332 LV 2 256 249 29.4 28.4 11.0 10.2 2 2 3 254 265 29.0 30.6 8.1 9.4 7 * 7 4 178 183 19.5 20.0 7.9 6.1 4 4 5 200 201 22.4 22.4 8.3 8.2 3 2 6 174 173 19.0 18.9 11.3 11.9 1 2 7 123 128 13.5 13.8 10.4 11.2 r 1 'Not all predicted sites are identical. While these studies demonstrated that VR-2332 was more closely related to the LV virus than were other members of the Arteriviridae, the homologies were much lower than expected for two viruses that cause the same disease; i.e., substitutions, deletions and additions occurred throughout the comparative sequences. The predicted proteins had different molecular weights, different isoelectric points, and different predicted glycosylation sites (Table 2). Although the amino acid homologies were substantially less than expected for viruses that appear to cause an identical disease, the findings were consistent with the striking antigenic diversity reported from serological studies by Wensvoort et al. These studies provided an explanation as to why there is observed little, if any, serological cross-reactivity between naturally occurring VR-2332 and LV antigens. Antigenic differences between VR-2332 and LV virus are due to immunological responses of swine to the dissimilar amino acid sequence regions of the viruses. EXAMPLE7 HYDROPATHYPROFILESTUDIES Other characteristics of the predicted proteins including the hydropathy profiles and percent basic character were compared. The results confirmed that the two viruses (LV and VR-2332) had functions and structures that were significantly more similar than was indicated by the amino acid comparison of Example 6 and immunological cross-reactivity reports. Comparative hydropathy profiles were created utilizing the EUGENE software package from Daniben Systems Inc. of Cincinnati, Ohio, based upon the deduced amino acid residue sequences for VR-2332 (Sequence ID Nos. 2-13) and LV virus (Sequence ID Nos. 14-26). These profiles indicated that the ORFs of VR-2332 and LV virus correspond structurally despite significant amino acid residue sequence differences. These results are consistent with the observed biological similarities, which contrast with the distinct serological properties between the VR-2332 and LV virus isolates. The hydropathy profiles compared each corresponding ORF in VR-2332 and the LV virus to indicate that protein structures and protein functions were conserved despite the extensive sequence differences. These profiles demonstrated highly similar regions of uncharged and charged amino acids, and are accurate predictors of similar functionality in membrane associated proteins of regions that either span or do not span the membrane. Thus, the VR-2332 proteins are similar in structure and function to those of LV virus, but extensive amino acid differences in the viral proteins account for the extensive differences in serological cross-reactivity. Figs. 3, 3A, 3B, and 3C depict the amino acid sequence alignment and hydropathy profiles for ORF 7 of VR-2332 (Sequence ID No. 13) and LV (Sequence ID No. 26). This ORF is located at the 3' end of the LV genome where the nucleocapsid protein has also been mapped in LDV and EAV, as reported by Godeny et al., Map location of lactate dehydrogenase-elevating virus (LDV) capsid protein (Vp1) gene, 177 Virol. 768-771 (1990), and de Vries et al., Structural proteins of equine arteritis virus, 66 J. Virol. 6294-6303 (1992). ORF 7 most likely forms the nucleocapsid protein in the PRRS virus. The protein was 64% similar between VR-2332 and LV virus, and VR-2332 ORF 7 was smaller by five amino acids. Nevertheless, the N-terminal half of both proteins encoded by ORF 7 was 26-28% basic and the hydrophobicity profiles were nearly identical. The basic residues presumably facilitate interactions with the RNA genome. Figs. 4, 4A, 4B, and 4C depict the amino acid sequence alignment and hydropathy profiles for ORF 6 of VR-2332 (Sequence ID No. 11) and LV (Sequence ID No.24). ORF 6 was the VR-2332 protein that was most similar to its LV virus counterpart, and was the only ORF that coded for an apparent amino terminal signal sequence. The LV and VR-2332 proteins shared 79% identity and one predicted glycosylation site (the LV virus had an additional site not found in VR-2332). Hydropathy profiles of ORF 6 of VR-2332, LV and EAV all showed three highly hydrophobic regions in the N-terminal half of the protein that indicate membrane spanning domains. These regions appear to be a conserved characteristic of all members of the Arteriviridae. Figs. 5, 5A, 5B, and 5C depict the amino acid sequence alignment and hydropathy profiles for ORF 5 of VR-2332 (Sequence ID No. 9) and LV (Sequence ID No. 22). ORF 5 appears to encode an envelope protein in the Arteriviridae because of its hydropathy profile and putative glycosylation sites. Similarly, according to de Vries et al. (see above) the G L or ORF 5 protein for EΞAV is glycosylated, VR-2332 ORF 5 contains three potential glycosylation sites, two of which are shared with LV. The LV and VR-2332 hydropathy profiles are highly similar although their percent identity (55%) was the lowest of all ORFs. In particular, only seven residues in the amino terminal 40 amino acids are the same, yet the hydropathy profiles are virtually identical. Potential membrane spanning domains between residues 65 and 130 are more pronounced in VR-2332. Figs. 6, 6A, 6B, and 6C depict the amino acid sequence alignment and hydropathy profiles for ORF 4 of VR-2332 (Sequence ID No. 7) and LV (Sequence ID No. 20). After ORF 6, ORF 4 is the most highly conserved ORF. The carboxyl terminus also is exceptionally hydrophobic in both viruses. Five putative membrane spanning domains are much more distinct in VR-2332 than in LV virus. Figs. 7, 7A, 7B, and 7C depict the amino acid sequence alignment and hydropathy profiles for ORF 3 of VR-2332 (Sequence ID No. 7) and LV (Sequence ID No. 18). ORF 3 is 60% similar between VR-2332 and LV virus. Nevertheless, ORF 3 is the least similar protein between the two viruses based on hydropathy profiles and by carboxyl terminal deletions of 12 amino acids in VR-2332. As a result of these differences, the corresponding LV protein has a strongly hydrophilic region centered on residue 240, whereas the VR-2332 protein appears amphipathic in this region. The nominal molecular mass of ORF 3 is approximately 30 kD, but it contains seven potential glycosylation sites in each virus, so that its apparent size can be significantly greater. Figs. 8, 8A, 8B, and 8C depict the amino acid sequence alignment and hydropathy profiles for ORF 2 of VR-2332 (Sequence ID No. 5) and LV (Sequence ID No. 16). ORF 2 was determined to be the largest of the 3' ORFs in VR-2332, and coded for the expression of 256 amino acids. It had a highly basic isoelectric point of 11.0, which was exceeded only by ORF 6, which had a pi of 11.3. The differences in amino acid sequence between VR-2332 and LV virus were distributed throughout the ORF, but the principal effect on the hydropathy profile appeared in the amino terminus. Fig. 9 VR-2332 depicts an alignment of the 3' untranslated sequence following ORF 7 in VR-2332 and LV virus. This region consisted of 151 nucleotides and a poly A tail of 19 to 20 bases in VR-2332. Similarly, the LV virus had a noncoding region of 115 bases. Bases 50-171 of the VR-2332 non-coding region of shared a strong homology to bases 13-135 of the LV non-coding region. EXAMPLE 8 ISOLATION OF VR-2332 RNA Viral RNA from infected cell supernatants is isolated for use in reverse transcription and PCR amplification reactions that selectively amplify either the VR-2332 or the LV viral nucleotides as a diagnostic tool for LV or PRRS. Additionally, PCR amplification is used to produce quantities of nucleotides for use in vaccines. As a diagnostic measure, swine lung tissue homogenates are preferably obtained by selecting tissue samples from alveolar abnormalities that are typical of PRRS; homogenizing these samples; mixing the homogenate with an appropriate physiological saline, e.g., Minimum Essential Medium, to a 10% (w/v) tissue concentration; and filtering the homogenate mixture through a series of filters having 0.45, 0.2 and 0.1 micron openings. The filtered homogenate is used as inoculum to infect cells of an appropriate cell line, e.g., monkey kidney cells or MA-104. The inoculated culture is incubated until a culture stock is obtained having a high virus titer from about log 5 to log 7. A first solution is prepared to include 5 M guanidinium isothiocyanate, 50 mM Tris HCI pH 7.5, 25 mM EDTA, 0.5 w/v Sarcosyl, and 1% (v/v)2-mercaptoethanol. A 10 ml aliquot of this solution is mixed with 100 microliters of 2-mercaptoethanol. A 2 ml portion of the virus stock culture is mixed in a tube with 2 ml of the first solution aliquot, as is 0.4 ml of 2 M sodium acetate, 4 ml phenol, and 1 ml of a chloroform-isoamyl alcohol solution mixed at a ratio of 24 parts of chloroform to 1 part of isoamyl alcohol. The virus- containing mixture is vortexed briefly after the addition of each reagent. The final mixture is vortexed for thirty seconds, chilled on ice for 15 seconds, then centrifuged at 8000 rpm for 20 minutes at 4°C in a JA-20 rotor. The aqueous phase will separate to the top upon centrifugation, and contains the RNA of interest. The aqueous phase is decanted and transferred to a new tube. About 4 ml of sterile water containing 2% by volume of diethylpyrocarbonate before autoclaving, is added to this second tube, as is 4 ml phenol, and 1.6 ml of the 24:1 chloroform-isoamyl alcohol mixture. These ingredients are vortexed, chilled on ice for 15 minutes, centrifuged at 8000 φm for 20 minutes at 4°C in a JA-20 rotor, and the aqueous phase is again extracted. The resultant aqueous extract is mixed with an equal volume of isopropanol, and chilled on ice for 1 hour to precipitate the RNA. The precipitated RNA is sedimented by centrifugation at 8000 φm for 20 minutes at 4°C in a JA-20 rotor. The isopropanol is decanted, and the invisible RNA pellet is dissolved in 0.3 ml of a solution containing 5 M guanidinium isothiocyanate, 50 mM Tris HCI pH 7.5, 25 mM EDTA, 0.5% Sarcosyl, and 1% 2-mercaptanol, and 0.1% 2-mercaptoethanol. The solution containing the dissolved pellet is transferred to a 1.5 ml microfuge tube, and the RNA is again precipitated with 0.3 ml of isopropanol for 1 hour on ice. The chilled solution is centrifuged at 15,000 φm in a microfuge for 10 minutes, after which the isopropanol is decanted. The resultant pellet is washed with about 0.5 ml of a solution containing 75% ethanol mixed with 25% water containing 0.2% diethyl pyrocarbonate by volume. After washing, the mixture is vortexed, and centrifuged for 5-10 minutes. The alcohol is decanted, and the RNA pellet is vacuum-dried for about 3 minutes. The pellet is dissolved in 50 ml of water containing 0.2% diethylpyrocarbonate by volume. EXAMPLE9 REVERSETRANSCRIPTIONOFRNATOFORMcDNA The solution from Example 8 containing RNA and the 0.2% diethylpyrocarbonate water is next subjected to reverse transcription of the RNA to produce complimentary fragments of cDNA. This procedure is preferably conducted by using commercially available kits, such as the RT-PCR kit from Perkin-Elmer. The kits are used according to the manufacturers instructions, which describe the proper use of kit reagents. By way of example, a master mixture is prepared from named reagents of the RT-PCR kit by mixing 4 ul MgCI 2 , 2 ul of 10X buffer, 2 ul dGTP, 2 ul dATP, 2 ul dCTP, 2 ul TTP, 1 ul RNase inhibitor, and 1 ul of reverse transcriptase. A 3 ul aliquot of the RNA and 0.2% diethylpyrocarbonate water mixture is placed into a microfuge tube taking care, if necessary, to dilute the aliquot with 0.2% diethylpyrocarbonate water so as to include no more than 1 μg of total RNA in the tube. The kit contains a mixture of random hexamers, and 1 ul of this mixture is added to the RNA and diethylpyrocarbonate water. The solution then is optionally heated to a temperature from about 65-70 °C for 5 to 10 minutes, and placed on ice. The 16 ul of master mix is added to the sample, and incubated at room temperature for about 10 minutes. Thereafter, the tube is incubated in a thermal cycler under the following conditions: 42°C for 15 minutes, 99°C for 5 minutes, and 5°C for 5 minutes. The tube is removed from the thermal cycler and stored at 4°C. The result of this reverse transcriptase reaction contains cDNA, which is subsequently subjected to PCR amplification. EXAMPLE 10 SELECTIVE PCR AMPLIFICATION OF cDNA In preparation for PCR amplification, a master mixture of the following reagents is prepared. 1 ul of MgCI 2 , 2 ul of 10X buffer, 0.5 ul of 5' primer, 0.5 ul of 3' primer, 15.875 ul of sterile water, and 0.125 ul of Taq polymerase. The 5' and 3' primers should have a concentration of approximately 10 uM, and are preferably comprised of synthetic nucleotides based upon the sequences listed below in Table 3. A 5 ul aliquot of the reverse transcriptase reaction solution from Example 9 is added to 20 ul of master mixture. The resultant 25 ul combination of master mixture and reverse transcriptase cDNA aliquot is overlain in a tube with 100 ul of mineral oil. The tube is incubated in a thermal cycler under the following conditions: 93 °C for 4 minutes for one cycle; 55°C for 30 seconds, 72°C for 45 seconds, and 93°C for 45 seconds, for 30 cycles; and 55 °C for 30 seconds, followed by 72 °C for 10 minutes for one cycle. After these 32 cycles, the solution is then maintained at 4°C until it is removed from the thermal cycler. The resultant solution, which contains PCR-amplified cDNA, is analyzed on an agarose gel. The preferred agarose gel includes 1.5% agarose mixed with TAE buffer, i.e., 1.5 grams of agarose per 100 ml of buffer. The mixture is melted in a microwave, and 1 ul of 10 mg/ml ethidium bromide solution is added per 100 ml of the gel. The mixture is poured into a casting stand, and allowed to harden for 30-45 minutes. A 5 ul aliquot of the PCR reaction solution is added into a tube, and 2 ul of a UV-sensitive running dye is added to the aliquot. An additional aliquot of 1-2 ul of an appropriate molecular weight marker is also added, such as a 100 base ladder from Gibco-BRL. The gel is placed in an electrophoresis chamber and the chamber is filled with a conventional TAE running buffer. Samples are loaded, and run at 80 volts for 1 hour. The electrophoresed PCR products are visualized under UV light. The PCR generated fragments that are visualized under UV light after the agarose gel electrophoresis are subjected to DNA sequencing for unambiguous confirmation of the identity of the viral nucleotide product. EXAMPLE 11 OLIGONUCLEOTIDE DESIGN FOR SELECTIVE PCR AMPLIFICATION OR HYBRIDIZATION The 5' and 3' primers that are used in the PCR amplification of Example 10 are preferably constructed, according to conventional protocols or on commercial order, as synthetic nucleotide sequences that replicate regions of interest in the VR-2332 genome. The primer design preferably includes selecting appropriate primers as the entire amino acid-coding sequences of the viral protein, selected ORFs, or, most preferably, coding regions for amino acid sequences representing protein fragments. The preferred oligonucleotides are selected to include those which specifically target small portions of the VR-2332 coding region, but are incapable of annealing with LV-derived nucleotides. These preferred oligonucleotides are used as primers for PCR amplification techniques to replicate long sequences of cDNA that are selected by the primers for use in vaccines and methods of vaccination. Similarly, the oligonucleotides are also used as probes for subsequent hybridization, cloning, and host expression of protein fragments and nucleotide products for subsequent use in vaccines. Preferred examples of the cDNA coding regions for expressed protein fragments that are selected for use in producing vaccines include those in which the translated amino acid terminal hydrophobic sequences are removed, as these terminal sequences are usually not present on mature forms of the viral protein. Selected cDNA coding regions can also code for protein fragments in which putative membrane-spanning sequences are removed, as the membrane-spanning sequences likely will not induce immune responses, and this removal generally simplifies the production of immunologically- sensitive proteins by recombinant DNA techniques. The sequences listed in Table 3 below represent exemplary primers with positional reference to the accompanying Sequence Listing. All sequences are provided in a 5' to 3' orientation. By way of example, Primer A represents the sequence 5 • -GCTGTTAAACAGGGAGTGG-3 , . Primer A' is the inverse compliment of the sequence S'-GTCACCTATTCAATTAGGG-S' (Sequence ID No. 1 positions 3271-3289), i.e., the sequence 5'- CCCTAATTGAATAGGTGAC-3'in which reverse-ordered complimentary nucleotides have been substituted for the sequence at positions 3271-3289. Table 3 Primer Description Positional Reference Seq. ID From To A VR-2332 ORF 7 based primer 2783 2801 A' VR-2332 ORF 7 based inverse 3271 3289 compliment of the VR-2332 sequence B VR-2332 ORF 6 based primer 2289 2307 B' VR-2332 ORF 6 based inverse 2862 2880 compliment of the VR-2332 sequence C LV ORF 6 based primer 14 14112 14131 C LV ORF 6 based inverse compliment of 14 14551 14570 the LV sequence D LV ORF 7 based primer 14 14575 14594 D * LV ORF 7 based inverse compliment of 14 14955 14974 the LV sequence E VR-2332 ORF 7 based primer * 2814 2832 E VR-2332 ORF 7 based inverse 3273 3291 compliment of the VR-2332 sequence ** F VR-2332 ORF 7 based primer *** 2816 2834 F VR-2332 ORF 7 based inverse 3181 3198 compliment of the VR-2332 sequence * * ** * A synthetic oligonucleotide may be constructed to include a BamHI restriction site with this sequence, i.e., the additional 5'-GCGGATCC nucleotides, for insertion into Pharmingen's pAcGP67B plasmid vector. ** A synthetic oligonucleotide may be constructed to include an inverse complimentary EcoRI restriction site with this sequence, i.e., the additional 5'- CCGAATTC nucleotides, for insertion into Pharmingen's pAcGP67B plasmid vector. ***A synthetic oligonucleotide may be constructed to include a Ndel restriction site with this sequence, i.e., the additional 5'-GCGCA nucleotides, for insertion into Novagen's pET25b plasmid vector. * ***A synthetic oligonucleotide may be constructed to include an inverse complimentary Hindlll restriction site with this sequence, i.e., the additional 5'- GCGAAGCT nucleotides, for insertion into Novagen's pET25b plasmid vector. Primers A and A' of Table 3 will selectively amplify the VR-2332 ORF 7 protein-coding nucleotides in a manner that distinguishes the VR-2332 nucleotides from other viral nucleotide isolates, including LV isolates. Similarly, Primers B and B' will selectively amplify the VR-2332 ORF 6 protein-coding nucleotides in a manner that distinguishes the VR-2332 nucleotides from other viral nucleotide isolates. On the other hand, Primers C and C, will selectively amplify the ORF 6 coding region of LV virus without amplifying VR-2332 ORF 6. Primers D and D' will selectively amplify LV ORF 7 without amplification of VR-2332 ORF 7. The preferred oligonucleotides of Table 3 are used for diagnosis of the specific PRRS-causative strain or virus through attempted PCR amplification of cDNA or conventional hybridization reactions. By way of example, if the PRRS signs are confirmed clinically in a diseased animal and if the primers that are specific for amplification of the Leiystad virus (e.g., Primers C, C and D, D') fail to produce cDNA amplification in the PCR reaction, then the absence of LV cDNA would be consistent with a diagnosis of VR-2332 infection. On the other hand, the failure of VR-2332 primers A, A' or B, B' in PCR amplification would be consistent with a diagnosis of LV infection. In cases where the presence of viral cDNA is confirmed by hybridization to these primer or probe sequences of Table 3, the hybridization occurs in solution with either cDNA or RNA affixed to a solid support such as nitrocellulose or nylon membranes. The recovered hybridized product is detected by conventional radioactive or non-radioactive techniques, which indicate the presence of viral nucleic acid sequence. Those skilled in the art will understand that an elementary list of diagnostic techniques includes dot- blot hybridization, slot-blot hybridization, solution hybridization, southern blot, northern blot, and RNase protection assays. EXAMPLE 12 CLONING OF VR-2332 PROTEIN CODING SEQUENCES IN HOST EXPRESSION SYSTEMS FOR THE PRODUCTION OF RECOMBINANTLY DERIVED VIRAL PROTEINS Selected portions of the VR-2332 nucleotide sequence (Sequence ID Nos. 1, 2, 4, 6, 8, 10, and 12) are used to clone an open reading frame, or a plurality of open reading frames, into a commercially available plasmid, that is designed for protein expression in a host organism. Examples of commercially available or self-designated systems that are used for the expression of viral proteins in eukaryotic or prokaryotic cells follow. The commercially available eukaryotic baculovirus system from Pharmingen of San Diego, California, which includes the vector pAcGP67B is preferred for use with Primers C and C. As indicated in Table 3, Primers C and C may be provided with respective BamHI and EcoRI restriction sites formed of synthetically joined nucleotides for use in linking these primers with the pAcGP67B vector. By this method, the resultant amplified cDNA would incoφorate substantially the entire coding region of VR-2332 ORF 7, and would also have a 5'-most BamHI site as well as a 3'-most EcoRI site. These restriction sites are used to place the VR-2332 coding region under the control of the appropriate pAcGP67B promoter and termination sequences for eukaryotic host expression of VR-2332 ORF 7 proteins. Prokaryotic host expression of viral proteins is accomplished in a variety of commercially available host expression systems. The PET system from NovaGen of Madison, Wisconsin is preferred for prokaryotic expression, and includes the vector pET25b. The PET system is preferred for use with Primers D and D', which may be provided with respective Ndel and Hindlll restriction sites for use in placing the VR-2332 ORF 7 coding region under the control of appropriate promoter and termination sequences. The protein corresponding to VR-2332 ORF 7 of Sequence ID Nos. 12 and 13 is expressed by amplifying selected protein coding sequences corresponding to the putative mature protein of ORF 7. This amplification procedure will follow the RT-PCR amplification procedure that is outlined in Examples 8, 9, and 10. The PCR primers are preferably designed to include Ndel and Hindlll restriction sites for cloning into the pET25b vector. These sites will result in a protein without a pelB leader or HisTag sequence, which provide alternative options for other expression systems. The mature protein is expressed without a signal peptide sequence by beginning the nucleotide sequence to code for either amino acid number 20 or number 30. The PCR fragments are cloned into the pET25b vector-amplified sequence and used in a host expression system. In selecting protein coding regions other than ORF 7, it is advantageous to delete or truncate certain protein coding regions, e.g., deletion of the membrane-spanning C-terminal 17 amino acids from ORF 4 will likely direct antibody responses to biologically relevant portions of the protein. The recombinant clones are transformed into BL21 cells for induction by isopropyl-β-D-thiogalactopyranoside ("IPTG"). After induction and an appropriate incubation, the expressed recombinant bioprotein is detected on a gel by comparing lysates from induced and uninduced ceils. Inclusion body preps are washed with urea or guanidine at a concentration that removes contaminating proteins without solubilizing the ORF 4 protein. Aggregates are resolublized in urea and refolded in oxidized and reduced glutathione. The resultant soluble, dialyzed protein is further purified by ion-exchange and size exclusion chromatography. EXAMPLE 13 INDUCTION OF AN IMMUNE RESPONSE IN AN ANIMAL BY INJECTION OF RECOMBINANT VIRAL PROTEINS The purified proteins from bacterial or eukaryotic expression systems, as produced in Example 12, are injected into animals by conventional immunization routes to elicit immune responses sufficient to immunize the animal against the VR-2332 strains of PRRS virus. The proteins alone, or in combination with a conventional adjuvant, are administered by intramuscular injection, intradermal injection, subcutaneous injection, or otherwise. As an alternative, live molecularly engineered bacteria or virus that express proteins corresponding to VR-2332 sequences are administered to animals by injection of the expression of VR-2332 proteins in vivo. This in vivo expression of recombinant proteins will also elicit an immune response to the VR-2332 virus. EXAMPLE 14 THE USE OF VR-2332 DNA TO INDUCE A DIRECT IMMUNE RESPONSE IN AN ANIMAL VR-2332 based oligonucleotide fragments, which code for ORFs or fragmentary portions of ORFs, are used to generate a direct immune response in an animal. This method generally follows the procedure described in Omer et al., 259 Science 1745-1749 (1993). The DNA is preferably included in plasmid constructs that are grown in bacteria, purified, and injected into animals by intramuscular injection, intradermal injection, or by other routes. The injected animal will typically express the cloned protein, and produce a corresponding immune response to the protein that is expressed. REFERENCES The following references pertain to PRRS viruses, and are hereby incorporated by reference herein. Benfield, D. A., Nelson, E., Collins, J. E., Harris, L., Goyal, S. M., Robison, D., Christianson, W. T., Morrison, R. B., Gorcyca, D. E., and Chladek, D. W. (1992). Characterization of swine infertility and respiratory syndrome (SIRS) virus (isolate ATCC VR-2332). J. Vet. Diagn. Invest. 4, 127-133. Chomczynski, P. and Sacchi, N. (1987). Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal. Biochem. 162, 156-159. Collins, J. E., Benfield, D. A., Christianson, W. T., Harris, L., Hennings, J. C, Shaw, D. P., Goyal, S. M., McCullough, S., Morrison, R. B., Joo, H. S., Gorcyca, D. E., and Chladek, D. W. (1992). Isolation of swine infertility and respiratory syndrome virus (isolate ATCC VR-2332) in North America and experimental reproduction of the disease in gnotobiotic pigs. J. Vet. Diagn. Invest. 4, 117-126. Conzelmann, K., Visser, N., Van Woensel, P. and Thiel, H. (1993). Molecular characterization of porcine reproductive and respiratory syndrome virus, a member of the arterivirus group. Virology 193, 329-339. den Boon, J. A., Snijder, E. J., Chimside, E. D., de Vries, A. A. F., Horzinek, M. C, and Spann, W. J. M. (1991). Equine arteritis virus is not a togavirus but belongs to the coronavirus superfamily. J. Virol. 65, 2910-2920. de Vries, A. A. F., Chimside, E. D., Horzinek, M. C, and Rottier, P. J. M. (1992). Structural proteins of equine arteritis virus. J. Virol. 66, 6294-6303. Godeny, E. K., Speicher, D. W., and Brinton, M. A. (1990). Map location of lactate dehydrogenase-elevating virus (LDV) capsid protein (Vp1) gene. Virol. 177, 768-771. Godeny, E. K., Zeng, L, Smith, S. L, and Brinton, M. A. (1993). In Proceedings of the 9th International Congress of Virology, p 22, August 8-13, Glasgow, Scotland. Gravell, M., W.T. London, M.E. Leon, A.E. Palmer and R.S. Hamilton. Proc. Soc. Exp. Biol. Med. 181, 112-119. Hill, H. (1990). Overview and History of Mystery Swine Disease (Swine Infertility and Respiratory syndrome). In: Proceedings of the Mystery Swine Disease Committee Meeting, October 6, Denver CO, pp. 29-30. Livestock Conservation Institute, Madison, Wl. Kuo, L., Harty, J. T., Erickson, L., Palmer, G. A., and Plagemann, P. G. W. (1991). A nested set of eight mRNAs is formed in macrophages infected with lactate dehydrogenase-elevating virus. J. Virol. 65, 5118-5123. Meuienberg, J. J. M., Hulst, M. M., de Veijer, E. J., Moonen, P. L J. M., den Besten, A., de Kluyver, E. P., Wensvoort, G., and Moormann, R. J. M. (1993). Leiystad virus, the causative agent of porcine epidemic abortion and respiratory syndrome (PEARS), is related to LDV and EAV. Virology 192, 62-72. Paton, D. J., Brown, I. H., Edwards., S. and Wensvoort, G. (1991). Blue ear disease of pigs. Vet Rec. 128, 617. Plagemann, P. G. W. and Moennig, V. (1992). Lactate dehydrogenase-elevating virus, equine arteritis virus and simian hemorrhagic fever virus: a new group of positive-strand RNA viruses. Adv. Vir. Res. 41 , 99-192. Pol, J. M. A., Van Dijk, J. E., Wensvoort, G., and Teφstra, C. (1991). Pathological, ultrastructural, and immunohistochemical changes caused by Leiystad virus in experimentally induced infections of mystery swine disease (synonym: porcine epidemic abortion and respiratory syndrome (PEARS))! Vet. Q. 13, 137-143. Spaan, W. J. M., Cavanagh, D. and Horzinek, M. C. (1988). Coronaviruses: structure and genome expression. J. Gen. Virol. 69, 2939-2952. Wensvoort, G., Teφstra, C, Pol, J. M. A., Ter Laak, E. A., Bloemraad, M., De Kluyver, E. P., Kragten, C, Van Buiten, L, Den Besten, A., Wagenaar, F., Broekhuijsen, J. M., Moonen, P. L. J. M., Zetstra.T., De Boer, E. A., Tibben, H. J., De Jong, M. F., Van't Veld, P., Groenland, G. J. R., Van Gennep, J. A., Voets, M. T., Verheijeden, J. H. M., and Braamskamp, J. (1991). Mystery swine disease in the Netherlands: the isolation of Leiystad virus. Vet. Q. 13, 121-130. Wensvoort, G., de Kluyver, E. P., Pol, J. M. A., Wagenaar, F., Moormann, R. J. M., Hulst, M. M. Bloemraad, R., den Besten, A., Zetstra, T. and Teφstra, C. (1992a). Leiystad virus, the cause of porcine epidemic abortion and respiratory syndrome: a review of mystery swine disease research at Leiystad. Vet. Micro. 33, 185-193. Wensvoort, G., de Kluyver, E. P., Lujtze, E. A., den Besten, A., Harris, L, Collins, J. E., Christianson, W. T. and Chladek, D. (1992b). Antigenic comparison of Leiystad virus and swine infertility and respiratory syndrome (SIRS) virus. J. Vet. Diagn. Invest. 4, 134-138. SEQUENCE LISTING (1) GENERAL INFORMATION: (i) APPLICANT: Murtaugh, Michael P. (ii) TITLE OF INVENTION: VR-2332 VIRAL NUCLEOTIDE SEQUENCE AND METHODS OF USE (iii) NUMBER OF SEQUENCES: 26 (iv) CORRESPONDENCE ADDRESS: (A) ADDRESSEE: John M. Collins (B) STREET: 1101 Walnut, Suite 1400 (C) CITY: Kansas City (D) STATE: Missouri (E) COUNTRY: USA (F) ZIP: 64106 (v) COMPUTER READABLE FORM: (A) MEDIUM TYPE: Floppy disk (B) COMPUTER: IBM PC compatible (C) OPERATING SYSTEM: PC-DOS/MS-DOS (D) SOFTWARE: Patentin Release #1.0, Version #1.25 (vi) CURRENT APPLICATION DATA: (A) APPLICATION NUMBER: (B) FILING DATE: (C) CLASSIFICATION: (viii) ATTORNEY/AGENT INFORMATION: (A) NAME: Collins, John M. (B) REGISTRATION NUMBER: 26122 (C) REFERENCE/DOCKET NUMBER: 22907 (ix) TELECOMMUNICATION INFORMATION: (A) TELEPHONE: (816) 474-9050 (B) TELEFAX: (816) 474-9057 (2) INFORMATION FOR SEQ ID NO:l: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 3358 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS :' double (D) TOPOLOGY: unknown (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (vi) ORIGINAL SOURCE: (A) ORGANISM: Arteriviridae (Unclassified) (B) STRAIN: VR-2332 (ix) FEATURE: (A) NAME/KEY: misc_feature (B) LOCATION: 1..768 (C) IDENTIFICATION METHOD: experimental (D) OTHER INFORMATION: /evidence= EXPERIMENTAL /standard_name= "VR-2332 ORF2" (ix) FEATURE: (A) NAME/KEY: misc_feature (B) LOCATION: 624..1385 (D) OTHER INFORMATION: /standard_name= "VR-2332 ORF 3" (ix) FEATURE: (A) NAME/KEY: misc_feature (B) LOCATION: 1169..1701 (D) OTHER INFORMATION: /standard_name= "VR-2332 ORF 4" (ix) FEATURE: (A) NAME/KEY: misc_feature (B) LOCATION: 1716..2315 (D) OTHER INFORMATION: /standard_name= "VR-2332 ORF 5" (ix) FEATURE: (A) NAME/KEY: misc_feature (B) LOCATION: 2303..2824 (D) OTHER INFORMATION: /standard_name= "VR-2332 ORF 6" (ix) FEATURE: (A) NAME/KEY: misc_feature (B) LOCATION: 2817..3185 (D) OTHER INFORMATION: /standard_name= "VR-2332 ORF 7" (xi) SEQUENCE DESCRIPTION: SEQ ID NO:l: ATGAAATGGG GTCCATGCAA AGCCTTTTTG ACAAAATTGG CCAACTTTTT GTGGATGCTT 60 TCACGGAGTT CTTGGTGTCC ATTGTTGATA TCATTATATT TTTGGCCATT TTGTTTGGCT 120 TCACCATCGC CGGTTGGCTG GTGGTCTTTT GCATCAGATT GGTTTGCTCC GCGATACTCC 180 GTACGCGCCC TGCCATTCAC TCTGAGCAAT TACAGAAGAT CTTATGAGGC CTTTCTTTCC 240 CAGTGCCAAG TGGACATTCC CACCTGGGGA ACTAAACATC CTTTGGGGAT GCTTTGGCAC 300 CATAAGGTGT CAACCCTGAT TGATGAAATG GTGTCGCGTC AATGTACCG CATCATGGAA 360 AAAGCAGGGC AGGCTGCCTG GAAACAGGTG GTGAGCGAGG CTACGCTGTC TCGCATTAGT 420 AGTTTGGATG TGGTGGCTCA TTTTCAGCAT CTAGCCGCCA TTGAAGCCGA GACCTGTAAA 480 TATTTGGCCT CCCGGCTGCC CATGCTACAC AACCTGCGCA TGACAGGGTC AAATGTAACC 540 ATAGTGTATA ATAGCACTTT GAATCAGGTG TTTGCTATTT TTCCAACCCC TGGTTCCCGG 600 CCAAAGCTTC ATGATTTTCA GCAATGGTTA ATAGCTGTAC ATTCCTCCAT ATTTTCCTCT 660 GTTGCAGCTT CTTGTACTCT TTTTGTTGTG CTGTGGTTGC GGGTTCCAAT ACTACGTACT 720 GTTTTTGGTT TCCGCTGGTT AGGGGCAATT TTTCTTTCGA ACTCACAGTG AATTACACGG 780 TGTGTCCACC TTGCCTCACC CGGCAAGCAG CCACAGAGAT TACGAACCC GGTAGGTCTC 840 TTTGGTGCAG GATAGGGTAT GACCGATGTG GGGAGGACGA TCATGACGAG CTAGGGTTTA 900 TGATACCGCC TGGCCTCTCC AGCGAAGGCC ACTTGACTGG TGTTTACGCC TGGTTGGCGT 960 TCTTGTCCTT CAGCTACACG GCCCAGTTCC ATCCCGAGAT ATTCGGGATA GGGAATGTGA 1020 GTCGAGTTTA TGTTGACATC AAACATCAAC TCATCTGCGC CGAACATGAC GGGCAGAACA 1080 CCACCTTGCC TCGTCATGAC AACATTTCAG CCGTGTTTCA GACCTATTAC CAACATCAAG 1140 TCGACGGCGG CAATTGGTTT CACCTAGAAT GGCTTCGTCC CTTCTTTTCC TCGTGGTTGG 1200 TTTTAAATGT CTCTTGGTTT CTCAGGCGTT CGCCTGCAAA CCATGTTTCA GTTCGAGTCT 1260 TGCAGATATT AAGACCAACA CCACCGCAGC GGCAAGCTTT GCTGTCCTCC AAGACATCAG 1320 TTGCCTTAGG CATCGCGACT CGGCCTCTGA GGCGATTCGC AAAATCCCTC AGTGCCGTAC 1380 GGCGATAGGG ACACCCGTGT ATGTTACCAT CACAGCCAAT GTGACAGATG AGAATTATTT 14 0 ACATTCTTCT GATCTCCTCA TGCTTTCTTC TTGCCTTTTC TATGCTTCTG AGATGAGTGA 1500 AAAGGGATTT AAGGTGGTAT TTGGCAATGT GTCAGGCATC GTGGCTGTGT GTGTCAATTT 1560 TACCAGCTAC GTCCAACATG TCAAGGAGTT TACCCAACGC TCCCTGGTGG TCGACCATGT 1620 GCGGTTGCTC CATTTCATGA CACCTGAGAC CATGAGGTGG GCAACTGTTT TAGCCTGTCT 1680 TTTTGCCATT CTGTTGGCAA TTTGAATGTT TAAGTATGTT GGAGAAATGC TTGACCGCGG 1740 GCTGTTGCTC GCGATTGCTT TCTTTGTGGT GTATCGTGCC GTTCTGTTTT GCTGTGCTCG 1800 CCAACGCCAG CAACGACAGC AGCTCCCATC TACAGCTGAT TTACAACTTG ACGCTATGTG 1860 AGCTGAATGG CACAGATTGG CTAGCTAACA AATTTGATTG GGCAGTGGAG AGTTTTGTCA 1920 TCTTTCCCGT TTTGACTCAC ATTGTCTCCT ATGGTGCCCT CACTACCAGC CATTTCCTTG 1980 ACACAGTCGC TTTAGTCACT GTGTCTACCG CCGGGTTTGT TCACGGGCGG TATGTCCTAA 20 0 GTAGCATCTA CGCGGTCTGT GCCCTGGCTG CGTTGACTTG CTTCGTCATT AGGTTTGCAA 2100 AGAATTGCAT GTCCTGGCGC TACGCGTGTA CCAGATATAC CAACTTTCTT CTGGACACTA 2160 AGGGCAGACT CTATCGTTGG CGGTCGCCTG TCATCATAGA GAAAAGGGGC AAAGTTGAGG 2220 TCGAAGGTCA TCTGATCGAC CTCAAAAGAG TTGTGCTTGA TGGTTCCGTG GCAACCCCTA 2280 TAACCAGAGT TTCAGCGGAA CAATGGGGTC GTCCTTAGAT GACTTCTGTC ATGATAGCAC 2340 GGCTCCACAA AAGGTGCTTT TGGCGTTTTC TATTACCTAC ACGCCAGTGA TGATATATGC 2400 CCTAAAGGTG AGTCGCGGCC GACTGCTAGG GCTTCTGCAC CTTTTGATCT TCCTGAATTG 2460 TGCTTTCACC TTCGGGTACA TGACTTTCGC GCACTTTCAG AGTACAAATA AGGTCGCGCT 2520 CACTATGGGA GCAGTAGTTG CACTCCTTTG GGGGGTGTAC TCAGCCATAG AAACCTGGAA 2580 ATTCATCACC TCCAGATGCC GTTTGTGCTT GCTAGGCCGC AAGTACATTC TGGCCCCTGC 2640 CCACCACGTT GAAAGTGCCG CACGGTTTCA TCCGATTGCG GCAAATGATA ACCACGCATT 2700 TGTCGTCCGG CGTCCCGGCT CCACTACGGT CAACGGCACA TTGGTGCCCG GGTTAAAAAG 2760 CCTCGTGTTG GGTGGCAGAA AAGCTGTTAA ACAGGGAGTG GTAAACCTTG TCAAATATGC 2820 CAAATAACAA CGGCAAGCAG ACAGAAGAGA AGAAGGGGGA TGGCCAGCCA GTCAATCAGC 2880 TGTGCCAGAT GCTGGGTAAG ATCATCGCTC AGCAAAACCA GTCCAGAGGC AAGGGACCGG 2940 GAAAGAAAAA TAAGAAGAAA AACCCGGAGA AGCCCCATTT TCCTCTAGCG ACTGAAGATG 3000 ATGTCAGACA TCACTTTACC CCTAGTGAGC GGCAATTGTG TCTGTCGTCA ATCCAGACCG 3060 CCTTTAATCA AGGCGCTGGG ACTTGCACCC TGTCAGATTC AGGGAGGATA AGTTACACTG 3120 TGGAGTTTAG TTTGCCTACG CATCATACTG TGCGCCTGAT CCGCGTCACA GCATCACCCT 3180 CAGCATGATG GGCTGGCATT CTTGAGGCAT CTCAGTGTTT GAATTGGAAG AATGTGTGGT 3240 GAATGGCACT GATTGACATT GTGCCTCTAA GTCACCTATT CAATTAGGGC GACCGTGTGG 3300 GGGTGAGATT TAATTGGCGA GAACCATGCG GCCGAAATTA AAAAAAAAAA AAAAAAAA 3358 (2) INFORMATION FOR SEQ ID NO:2: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 768 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 1..768 (C) IDENTIFICATION METHOD: experimental (D) OTHER INFORMATION: /evidence= EXPERIMENTAL /standard name= "VR-2332 ORF 2" (xi) SEQUENCE DESCRIPTION: SEQ ID NO:2: ATG AAA TGG GGT CCA TGC AAA GCC TTT TTG ACA AAA TTG GCC AAC TTT 48 Met Lys Trp Gly Pro Cys Lys Ala Phe Leu Thr Lys Leu Ala Asn Phe 1 5 10 15 TTG TGG ATG CTT TCA CGG AGT TCT TGG TGT CCA TTG TTG ATA TCA TTA 96 Leu Trp Met Leu Ser Arg Ser Ser Trp Cys Pro Leu Leu lie Ser Leu 20 25 30 TAT TTT TGG CCA TTT TGT TTG GCT TCA CCA TCG CCG GTT GGC TGG TGG 144 Tyr Phe Trp Pro Phe Cys Leu Ala Ser Pro Ser Pro Val Gly Trp Trp 35 40 45 TCT TTT GCA TCA GAT TGG TTT GCT CCG CGA TAC TCC GTA CGC GCC CTG 192 Ser Phe Ala Ser Asp Trp Phe Ala Pro Arg Tyr Ser Val Arg Ala Leu 50 55 60 CCA TTC ACT CTG AGC AAT TAC AGA AGA TCT TAT GAG GCC TTT CTT TCC 240 Pro Phe Thr Leu Ser Asn Tyr Arg Arg Ser Tyr Glu Ala Phe Leu Ser 65 70 75 80 CAG TGC CAA GTG GAC ATT CCC ACC TGG GGA ACT AAA CAT CCT TTG GGG 288 Gin Cys Gin Val Asp lie Pro Thr Trp Gly Thr Lys His Pro Leu Gly 85 90 95 ATG CTT TGG CAC CAT AAG GTG TCA ACC CTG ATT GAT GAA ATG GTG TCG 336 Met Leu Trp His His Lys Val Ser Thr Leu lie Asp Glu Met Val Ser 100 105 110 CGT CGA ATG TAC CGC ATC ATG GAA AAA GCA GGG CAG GCT GCC TGG AAA 384 Arg Arg Met Tyr Arg lie Met Glu Lys Ala Gly Gin Ala Ala Trp Lys 115 120 125 CAG GTG GTG AGC GAG GCT ACG CTG TCT CGC ATT AGT AGT TTG GAT GTG 432 Gin Val Val Ser Glu Ala Thr Leu Ser Arg lie Ser Ser Leu Asp Val 130 135 140 GTG GCT CAT TTT CAG CAT CTA GCC GCC ATT GAA GCC GAG ACC TGT AAA 480 Val Ala His Phe Gin His Leu Ala Ala lie Glu Ala Glu Thr Cys Lys 145 150 155 160 TAT TTG GCC TCC CGG CTG CCC ATG CTA CAC AAC CTG CGC ATG ACA GGG 528 Tyr Leu Ala Ser Arg Leu Pro Met Leu His Asn Leu Arg Met Thr Gly 165 170 175 TCA AAT GTA ACC ATA GTG TAT AAT AGC ACT TTG AAT CAG GTG TTT GCT 576 Ser Asn Val Thr lie Val Tyr Asn Ser Thr Leu Asn Gin Val Phe Ala 180 185 190 ATT TTT CCA ACC CCT GGT TCC CGG CCA AAG CTT CAT GAT TTT CAG CAA 624 lie Phe Pro Thr Pro Gly Ser Arg Pro Lys Leu His Asp Phe Gin Gin 195 200 205 TGG TTA ATA GCT GTA CAT TCC TCC ATA TTT TCC TCT GTT GCA GCT TCT 672 Trp Leu lie Ala Val His Ser Ser lie Phe Ser Ser Val Ala Ala Ser 210 215 220 TGT ACT CTT TTT GTT GTG CTG TGG TTG CGG GTT CCA ATA CTA CGT ACT 720 Cys Thr Leu Phe Val Val Leu Trp Leu Arg Val Pro lie Leu Arg Thr 225 230 235 240 GTT TTT GGT TTC CGC TGG TTA GGG GCA ATT TTT CTT TCG AAC TCA CAG 768 Val Phe Gly Phe Arg Trp Leu Gly Ala lie Phe Leu Ser Asn Ser Gin 245 250 255 (2) INFORMATION FOR SEQ ID NO:3: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 256 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (Xi) SEQUENCE DESCRIPTION: SEQ ID NO:3: Met Lys Trp Gly Pro Cys Lys Ala Phe Leu Thr Lys Leu Ala Asn Phe 1 5 10 15 Leu Trp Met Leu Ser Arg Ser Ser Trp Cys Pro Leu Leu lie Ser Leu 20 25 30 Tyr Phe Trp Pro Phe Cys Leu Ala Ser Pro Ser Pro Val Gly Trp Trp 35 40 45 Ser Phe Ala Ser Asp Trp Phe Ala Pro Arg Tyr Ser Val Arg Ala Leu 50 55 60 Pro Phe Thr Leu Ser Asn Tyr Arg Arg Ser Tyr Glu Ala Phe Leu Ser 65 70 75 80 Gin Cys Gin Val Asp lie Pro Thr Trp Gly Thr Lys His Pro Leu Gly 85 90 95 Met Leu Trp His His Lys Val Ser Thr Leu lie Asp Glu Met Val Ser 100 105 110 Arg Arg Met Tyr Arg lie Met Glu Lys Ala Gly Gin Ala Ala Trp Lys 115 120 125 Gin Val Val Ser Glu Ala Thr Leu Ser Arg lie Ser Ser Leu Asp Val 130 135 140 Val Ala His Phe Gin His Leu Ala Ala lie Glu Ala Glu Thr Cys Lys 145 150 155 160 Tyr Leu Ala Ser Arg Leu Pro Met Leu His Asn Leu Arg Met Thr Gly 165 170 175 Ser Asn Val Thr lie Val Tyr Asn Ser Thr Leu Asn Gin Val Phe Ala 180 185 190 lie Phe Pro Thr Pro Gly Ser Arg Pro Lys Leu His Asp Phe Gin Gin 195 200 205 Trp Leu lie Ala Val His Ser Ser He Phe Ser Ser Val Ala Ala Ser 210 215 220 Cys Thr Leu Phe Val Val Leu Trp Leu Arg Val Pro He Leu Arg Thr 225 230 235 240 Val Phe Gly Phe Arg Trp Leu Gly Ala He Phe Leu Ser Asn Ser Gin 245 250 255 (2) INFORMATION FOR SEQ ID NO:4: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 762 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS : double (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 1..762 (C) IDENTIFICATION METHOD: experimental (D) OTHER INFORMATION: /evidence= EXPERIMENTAL /standard name= "VR-2332 ORF 3" (xi) SEQUENCE DESCRIPTION: SEQ ID NO:4: ATG GTT AAT AGC TGT ACA TTC CTC CAT ATT TTC CTC TGT TGC AGC TTC 48 Met Val Asn Ser Cys Thr Phe Leu His He Phe Leu Cys Cys Ser Phe 1 5 10 15 TTG TAC TCT TTT TGT TGT GCT GTG GTT GCG GGT TCC AAT ACT ACG TAC 96 Leu Tyr Ser Phe Cys Cys Ala Val Val Ala Gly Ser Asn Thr Thr Tyr 20 25 30 TGT TTT TGG TTT CCG CTG GTT AGG GGC AAT TTT TCT TTC GAA CTC ACA 144 Cys Phe Trp Phe Pro Leu Val Arg Gly Asn Phe Ser Phe Glu Leu Thr 35 40 45 GTG AAT TAC ACG GTG TGT CCA CCT TGC CTC ACC CGG CAA GCA GCC ACA 192 Val Asn Tyr Thr Val Cys Pro Pro Cys Leu Thr Arg Gin Ala Ala Thr 50 55 60 GAG ATC TAC GAA CCC GGT AGG TCT CTT TGG TGC AGG ATA GGG TAT GAC 240 Glu He Tyr Glu Pro Gly Arg Ser Leu Trp Cys Arg He Gly Tyr Asp 65 70 75 80 CGA TGT GGG GAG GAC GAT CAT GAC GAG CTA GGG TTT ATG ATA CCG CCT 288 Arg Cys Gly Glu Asp Asp His Asp Glu Leu Gly Phe Met He Pro Pro 85 90 95 GGC CTC TCC AGC GAA GGC CAC TTG ACT GGT GTT TAC GCC TGG TTG GCG 336 Gly Leu Ser Ser Glu Gly His Leu Thr Gly Val Tyr Ala Trp Leu Ala 100 105 110 TTC TTG TCC TTC AGC TAC ACG GCC CAG TTC CAT CCC GAG ATA TTC GGG 384 Phe Leu Ser Phe Ser Tyr Thr Ala Gin Phe His 9ro Glu He Phe Gly 115 120 125 ATA GGG AAT GTG AGT CGA GTT TAT GTT GAC ATC AAA CAT CAA CTC ATC 432 He Gly Asn Val Ser Arg Val Tyr Val Asp He Lys His Gin Leu He 130 135 140 TGC GCC GAA CAT GAC GGG CAG AAC ACC ACC TTG CCT CGT CAT GAC AAC 480 Cys Ala Glu His Asp Gly Gin Asn Thr Thr Leu Pro Arg His Asp Asn 145 150 155 160 ATT TCA GCC GTG TTT CAG ACC TAT TAC CAA CAT CAA GTC GAC GGC GGC 528 He Ser Ala Val Phe Gin Thr Tyr Tyr Gin His Gin Val Asp Gly Gly 165 170 175 AAT TGG TTT CAC CTA GAA TGG CTT CGT CCC TTC TTT TCC TCG TGG TTG 576 Asn Trp Phe His Leu Glu Trp Leu Arg Pro Phe Phe Ser Ser Trp Leu 180 185 190 GTT TTA AAT GTC TCT TGG TTT CTC AGG CGT TCG CCT GCA AAC CAT GTT 624 Val Leu Asn Val Ser Trp Phe Leu Arg Arg Ser Pro Ala Asn His Val 195 200 205 TCA GTT CGA GTC TTG CAG ATA TTA AGA CCA ACA CCA CCG CAG CGG CAA 672 Ser Val Arg Val Leu Gin He Leu Arg Pro Thr Pro Pro Gin Arg Gin 210 215 220 GCT TTG CTG TCC TCC AAG ACA TCA GTT GCC TTA GGC ATC GCG ACT CGG 720 Ala Leu Leu Ser Ser Lys Thr Ser Val Ala Leu Gly He Ala Thr Arg 225 230 235 240 CCT CTG AGG CGA TTC GCA AAA TCC CTC AGT GCC GTA CGG CGA 762 Pro Leu Arg Arg Phe Ala Lys Ser Leu Ser Ala Val Arg Arg 245 250 (2) INFORMATION FOR SEQ ID NO:5: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 254 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:5: Met Val Asn Ser Cys Thr Phe Leu His He Phe Leu Cys Cys Ser Phe 1 5 10 15 Leu Tyr Ser Phe Cys Cys Ala Val Val Ala Gly Ser Asn Thr Thr Tyr 20 25 30 Cys Phe Trp Phe Pro Leu Val Arg Gly Asn Phe Ser Phe Glu Leu Thr 35 40 45 Val Asn Tyr Thr Val Cys Pro Pro Cys Leu Thr Arg Gin Ala Ala Thr 50 55 60 Glu He Tyr Glu Pro Gly Arg Ser Leu Trp Cys Arg He Gly Tyr Asp 65 70 75 80 Arg Cys Gly Glu Asp Asp His Asp Glu Leu Gly Phe Met He Pro Pro 85 90 95 Gly Leu Ser Ser Glu Gly His Leu Thr Gly Val Tyr Ala Trp Leu Ala 100 105 110 Phe Leu Ser Phe Ser Tyr Thr Ala Gin Phe His Pro Glu He Phe Gly 115 120 125 He Gly Asn Val Ser Arg Val Tyr Val Asp He Lys His Gin Leu He 130 135 140 Cys Ala Glu His Asp Gly Gin Asn Thr Thr Leu Pro Arg His Asp Asn 145 150 155 160 He Ser Ala Val Phe Gin Thr Tyr Tyr Gin His Gin Val Asp Gly Gly 165 170 175 Asn Trp Phe His Leu Glu Trp Leu Arg Pro Phe Phe Ser Ser Trp Leu 180 185 190 Val Leu Asn Val Ser Trp Phe Leu Arg Arg Ser Pro Ala Asn His Val 195 200 205 Ser Val Arg Val Leu Gin He Leu Arg Pro Thr Pro Pro Gin Arg Gin 210 215 • 220 Ala Leu Leu Ser Ser Lys Thr Ser Val Ala Leu Gly He Ala Thr Arg 225 230 235 240 Pro Leu Arg Arg Phe Ala Lys Ser Leu Ser Ala Val Arg Arg 245 250 (2) INFORMATION FOR SEQ ID NO:6: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 534 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS : double (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 1..534 (C) IDENTIFICATION METHOD: experimental (D) OTHER INFORMATION: /evidence EXPERIMENTAL /standard name= "VR-2332 ORF 4" (xi) SEQUENCE DESCRIPTION: SEQ ID NO:6: ATG GCT TCG TCC CTT CTT TTC CTC GTG GTT GGT TTT AAA TGT CTC TTG 48 Met Ala Ser Ser Leu Leu Phe Leu Val Val Gly Phe Lys Cys Leu Leu 1 5 10 15 GTT TCT CAG GCG TTC GCC TGC AAA CCA TGT TTC AGT TCG AGT CTT GCA 96 Val Ser Gin Ala Phe Ala Cys Lys Pro Cys Phe Ser Ser Ser Leu Ala 20 25 30 GAT ATT AAG ACC AAC ACC ACC GCA GCG GCA AGC TTT GCT GTC CTC CAA 144 Asp He Lys Thr Asn Thr Thr Ala Ala Ala Ser Phe Ala Val Leu Gin 35 40 45 GAC ATC AGT TGC CTT AGG CAT CGC GAC TCG GCC TCT GAG GCG ATT CGC 192 Asp He Ser Cys Leu Arg His Arg Asp Ser Ala Ser Glu Ala He Arg 50 55 60 AAA ATC CCT CAG TGC CGT ACG GCG ATA GGG ACA CCC GTG TAT GTT ACC 240 Lys He Pro Gin Cys Arg Thr Ala He Gly Thr Pro Val Tyr Val Thr 65 70 75 80 ATC ACA GCC AAT GTG ACA GAT GAG AAT TAT TTA CAT TCT TCT GAT CTC 288 He Thr Ala Asn Val Thr Asp Glu Asn Tyr Leu His Ser Ser Asp Leu 85 90 95 CTC ATG CTT TCT TCT TGC CTT TTC TAT GCT TCT GAG ATG AGT GAA AAG 336 Leu Met Leu Ser Ser Cys Leu Phe Tyr Ala Ser Glu Met Ser Glu Lys 100 105 110 GGA TTT AAG GTG GTA TTT GGC AAT GTG TCA GGC ATC GTG GCT GTG TGT 384 Gly Phe Lys Val Val Phe Gly Asn Val Ser Gly He Val Ala Val Cys 115 120 125 GTC AAT TTT ACC AGC TAC GTC CAA CAT GTC AAG GAG TTT ACC CAA CGC 432 Val Asn Phe Thr Ser Tyr Val Gin His Val Lys Glu Phe Thr Gin Arg 130 135 140 TCC CTG GTG GTC GAC CAT GTG CGG TTG CTC CAT TTC ATG ACA CCT GAG 480 Ser Leu Val Val Asp His Val Arg Leu Leu His Phe Met Thr Pro Glu 145 150 155 160 ACC ATG AGG TGG GCA ACT GTT TTA GCC TGT CTT TTT GCC ATT CTG TTG 528 Thr Met Arg Trp Ala Thr Val Leu Ala Cys Leu Phe Ala He Leu Leu 165 170 175 GCA ATT 534 Ala He (2) INFORMATION FOR SEQ ID NO:7 : (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 178 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:7: Met Ala Ser Ser Leu Leu Phe Leu Val Val Gly Phe Lys Cys Leu Leu 1 5 10 15 Val Ser Gin Ala Phe Ala Cys Lys Pro Cys Phe Ser Ser Ser Leu Ala 20 25 30 Asp He Lys Thr Asn Thr Thr Ala Ala Ala Ser Phe Ala Val Leu Gin 35 40 45 Asp He Ser Cys Leu Arg His Arg Asp Ser Ala Ser Glu Ala He Arg 50 55 60 Lys He Pro Gin Cys Arg Thr Ala He Gly Thr Pro Val Tyr Val Thr 65 70 75 80 He Thr Ala Asn Val Thr Asp Glu Asn Tyr Leu His Ser Ser Asp Leu 85 90 95 Leu Met Leu Ser Ser Cys Leu Phe Tyr Ala Ser Glu Met Ser Glu Lys 100 105 110 Gly Phe Lys Val Val Phe Gly Asn Val Ser Gly He Val Ala Val Cys 115 120 125 Val Asn Phe Thr Ser Tyr Val Gin His Val Lys Glu Phe Thr Gin Arg 130 135 140 Ser Leu Val Val Asp His Val Arg Leu Leu His Phe Met Thr Pro Glu 145 150 155 160 Thr Met Arg Trp Ala Thr Val Leu Ala Cys Leu Phe Ala He Leu Leu 165 170 175 Ala He (2) INFORMATION FOR SEQ ID NO:8: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 600 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 1..600 (C) IDENTIFICATION METHOD: experimental (D) OTHER INFORMATION: /evidence- EXPERIMENTAL /standard name= "VR-2332 ORF5" (xi) SEQUENCE DESCRIPTION: SEQ ID NO:8: ATG TTG GAG AAA TGC TTG ACC GCG GGC TGT TGC TCG CGA TTG CTT TCT 48 Met Leu Glu Lys Cys Leu Thr Ala Gly Cys Cys Ser Arg Leu Leu Ser 1 5 10 15 TTG TGG TGT ATC GTG CCG TTC TGT TTT GCT GTG CTC GCC AAC GCC AGC 96 Leu Trp Cys He Val Pro Phe Cys Phe Ala Val Leu Ala Asn Ala Ser 20 25 30 AAC GAC AGC AGC TCC CAT CTA CAG CTG ATT TAC AAC TTG ACG CTA TGT 144 Asn Asp Ser Ser Ser His Leu Gin Leu He Tyr Asn Leu Thr Leu Cys 35 40 45 GAG CTG AAT GGC ACA GAT TGG CTA GCT AAC AAA TTT GAT TGG GCA GTG 192 Glu Leu Asn Gly Thr Asp Trp Leu Ala Asn Lys Phe Asp Trp Ala Val 50 55 60 GAG AGT TTT GTC ATC TTT CCC GTT TTG ACT CAC ATT GTC TCC TAT GGT 240 Glu Ser Phe Val He Phe Pro Val Leu Thr His He Val Ser Tyr Gly 65 70 75 80 GCC CTC ACT ACC AGC CAT TTC CTT GAC ACA GTC GCT TTA GTC ACT GTG 288 Ala Leu Thr Thr Ser His Phe Leu Asp Thr Val Ala Leu Val Thr Val 85 90 95 TCT ACC GCC GGG TTT GTT CAC GGG CGG TAT GTC CTA AGT AGC ATC TAC 336 Ser Thr Ala Gly Phe Val His Gly Arg Tyr Val Leu Ser Ser He Tyr 100 105 110 GCG GTC TGT GCC CTG GCT GCG TTG ACT TGC TTC GTC ATT AGG TTT GCA 384 Ala Val Cys Ala Leu Ala Ala Leu Thr Cys Phe Val He Arg Phe Ala 115 120 125 AAG AAT TGC ATG TCC TGG CGC TAC GCG TGT ACC AGA TAT ACC AAC TTT 432 Lys Asn Cys Met Ser Trp Arg Tyr Ala Cys Thr Arg Tyr Thr Asn Phe 130 135 140 CTT CTG GAC ACT AAG GGC AGA CTC TAT CGT TGG CGG TCG CCT GTC ATC 480 Leu Leu Asp Thr Lys Gly Arg Leu Tyr Arg Trp Arg Ser Pro Val He 145 150 155 160 ATA GAG AAA AGG GGC AAA GTT GAG GTC GAA GGT CAT CTG ATC GAC CTC 528 He Glu Lys Arg Gly Lys Val Glu Val Glu Gly His Leu He Asp Leu 165 170 175 AAA AGA GTT GTG CTT GAT GGT TCC GTG GCA ACC CCT ATA ACC AGA GTT 576 Lys Arg Val Val Leu Asp Gly Ser Val Ala Thr Pro He Thr Arg Val 180 185 190 TCA GCG GAA CAA TGG GGT CGT CCT 600 Ser Ala Glu Gin Trp Gly Arg Pro 195 200 (2) INFORMATION FOR SEQ ID NO:9: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 200 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:9: Met Leu Glu Lys Cys Leu Thr Ala Gly Cys Cys Ser Arg Leu Leu Ser 1 5 10 15 Leu Trp Cys He Val Pro Phe Cys Phe Ala Val Leu Ala Asn Ala Ser 20 25 30 Asn Asp Ser Ser Ser His Leu Gin Leu He Tyr Asn Leu Thr Leu Cys 35 40 45 Glu Leu Asn Gly Thr Asp Trp ' Leu Ala Asn Lys Phe Asp Trp Ala Val 50 55 60 Glu Ser Phe Val He Phe Pro Val Leu Thr His He Val Ser Tyr Gly 65 70 75 80 Ala Leu Thr Thr Ser His Phe Leu Asp Thr Val Ala Leu Val Thr Val 85 90 95 Ser Thr Ala Gly Phe Val His Gly Arg Tyr Val Leu Ser Ser He Tyr 100 105 110 Ala Val Cys Ala Leu Ala Ala Leu Thr Cys Phe Val He Arg Phe Ala 115 120 125 Lys Asn Cys Met Ser Trp Arg Tyr Ala Cys Thr Arg Tyr Thr Asn Phe 130 135 140 Leu Leu Asp Thr Lys Gly Arg Leu Tyr Arg Trp Arg Ser Pro Val He 145 150 155 160 He Glu Lys Arg Gly Lys Val Glu Val Glu Gly His Leu He Asp Leu 165 170 175 Lys Arg Val Val Leu Asp Gly Ser Val Ala Thr Pro He Thr Arg Val 180 185 190 Ser Ala Glu Gin Trp Gly Arg Pro 195 200 (2) INFORMATION FOR SEQ ID NO:10: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 522 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 1..522 (C) IDENTIFICATION METHOD: experimental (D) OTHER INFORMATION: /evidence- EXPERIMENTAL /standard name- "VR-2332 ORF 6" (xi) SEQUENCE DESCRIPTION: SEQ ID NO:10: ATG GGG TCG TCC TTA GAT GAC TTC TGT CAT GAT AGC ACG GCT CCA CAA 48 Met Gly Ser Ser Leu Asp Asp Phe Cys His Asp Ser Thr Ala Pro Gin 1 5 10 15 AAG GTG CTT TTG GCG TTT TCT ATT ACC TAC ACG CCA GTG ATG ATA TAT 96 Lys Val Leu Leu Ala Phe Ser He Thr Tyr Thr Pro Val Met He Tyr 20 25 30 GCC CTA AAG GTG AGT CGC GGC CGA CTG CTA GGG CTT CTG CAC CTT TTG 144 Ala Leu Lys Val Ser Arg Gly Arg Leu Leu Gly Leu Leu His Leu Leu 35 40 45 ATC TTC CTG AAT TGT GCT TTC ACC TTC GGG TAC ATG ACT TTC GCG CAC 192 He Phe Leu Asn Cys Ala Phe Thr Phe Gly Tyr Met Thr Phe Ala His 50 55 60 TTT CAG AGT ACA AAT AAG GTC GCG CTC ACT ATG GGA GCA GTA GTT GCA 240 Phe Gin Ser Thr Asn Lys Val Ala Leu Thr Met Gly Ala Val Val Ala 65 70 75 80 CTC CTT TGG GGG GTG TAC TCA GCC ATA GAA ACC TGG AAA TTC ATC ACC 288 Leu Leu Trp Gly Val Tyr Ser Ala He Glu Thr Trp Lys Phe He Thr 85 90 95 TCC AGA TGC CGT TTG TGC TTG CTA GGC CGC AAG TAC ATT CTG GCC CCT 336 Ser Arg Cys Arg Leu Cys Leu Leu Gly Arg Lys Tyr He Leu Ala Pro 100 105 110 GCC CAC CAC GTT GAA AGT GCC GCA CGG TTT CAT CCG ATT GCG GCA AAT 384 Ala His His Val Glu Ser Ala Ala Arg Phe His Pro He Ala Ala Asn 115 120 125 GAT AAC CAC GCA TTT GTC GTC CGG CGT CCC GGC TCC ACT ACG GTC AAC 432 Asp Asn His Ala Phe Val Val Arg Arg Pro Gly Ser Thr Thr Val Asn 130 135 140 GGC ACA TTG GTG CCC GGG TTA AAA AGC CTC GTG TTG GGT GGC AGA AAA 480 Gly Thr Leu Val Pro Gly Leu Lys Ser Leu Val Leu Gly Gly Arg Lys 145 150 155 160 GCT GTT AAA CAG GGA GTG GTA AAC CTT GTC AAA TAT GCC AAA 522 Ala Val Lys Gin Gly Val Val Asn Leu Val Lys Tyr Ala Lys 165 170 (2) INFORMATION FOR SEQ ID NO:11: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 174 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:11: Met Gly Ser Ser Leu Asp Asp Phe Cys His Asp Ser Thr Ala Pro Gin 1 5 10 15 Lys Val Leu Leu Ala Phe Ser He Thr Tyr Thr Pro Val Met He Tyr 20 25 30 Ala Leu Lys Val Ser Arg Gly Arg Leu Leu Gly Leu Leu His Leu Leu 35 40 45 He Phe Leu Asn Cys Ala Phe Thr Phe Gly Tyr Met Thr Phe Ala His 50 55 60 Phe Gin Ser Thr Asn Lys Val Ala Leu Thr Met Gly Ala Val Val Ala 65 70 75 80 Leu Leu Trp Gly Val Tyr Ser Ala He Glu Thr Trp Lys Phe He Thr 85 90 95 Ser Arg Cys Arg Leu Cys Leu Leu Gly Arg Lys Tyr He Leu Ala Pro 100 105 110 Ala His His Val Glu Ser Ala Ala Arg Phe His Pro He Ala Ala Asn 115 120 125 Asp Asn His Ala Phe Val Val Arg Arg Pro Gly Ser Thr Thr Val Asn 130 135 140 Gly Thr Leu Val Pro Gly Leu Lys Ser Leu Val Leu Gly Gly Arg Lys 145 150 155 160 Ala Val Lys Gin Gly Val Val Asn Leu Val Lys Tyr Ala Lys 165 170 (2) INFORMATION FOR SEQ ID NO:12: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 369 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 1..369 (C) IDENTIFICATION METHOD: experimental (D) OTHER INFORMATION: /evidence- EXPERIMENTAL /standard name- "VR-2332 ORF 7" (xi) SEQUENCE DESCRIPTION: SEQ ID NO:12: ATG CCA AAT AAC AAC GGC AAG CAG ACA GAA GAG AAG AAG GGG GAT GGC 48 Met Pro Asn Asn Asn Gly Lys Gin Thr Glu Glu Lys Lys Gly Asp Gly 1 5 10 15 CAG CCA GTC AAT CAG CTG TGC CAG ATG CTG GGT AAG ATC ATC GCT CAG 96 Gin Pro Val Asn Gin Leu Cys Gin Met Leu Gly Lys He He Ala Gin 20 25 30 CAA AAC CAG TCC AGA GGC AAG GGA CCG GGA AAG AAA AAT AAG AAG AAA 144 Gin Asn Gin Ser Arg Gly Lys Gly Pro Gly Lys Lys Asn Lys Lys Lys 35 40 45 AAC CCG GAG AAG CCC CAT TTT CCT CTA GCG ACT GAA GAT GAT GTC AGA 192 Asn Pro Glu Lys Pro His Phe Pro Leu Ala Thr Glu Asp Asp Val Arg 50 55 60 CAT CAC TTT ACC CCT AGT GAG CGG CAA TTG TGT CTG TCG TCA ATC CAG 240 His His Phe Thr Pro Ser Glu Arg Gin Leu Cys Leu Ser Ser He Gin 65 70 75 80 ACC GCC TTT AAT CAA GGC GCT GGG ACT TGC ACC CTG TCA GAT TCA GGG 288 Thr Ala Phe Asn Gin Gly Ala Gly Thr Cys Thr Leu Ser Asp Ser Gly 85 90 95 AGG ATA AGT TAC ACT GTG GAG TTT AGT TTG CCT ACG CAT CAT ACT GTG 336 Arg He Ser Tyr Thr Val Glu Phe Ser Leu Pro Thr His His Thr Val 100 105 110 CGC CTG ATC CGC GTC ACA GCA TCA CCC TCA GCA 369 Arg Leu He Arg Val Thr Ala Ser Pro Ser Ala 115 120 (2) INFORMATION FOR SEQ ID NO:13: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 123 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:13: Met Pro Asn Asn Asn Gly Lys Gin Thr Glu Glu Lys Lys Gly Asp Gly 1 5 10 15 Gin Pro Val Asn Gin Leu Cys Gin Met Leu Gly Lys He He Ala Gin 20 25 30 Gin Asn Gin Ser Arg Gly Lys Gly Pro Gly Lys Lys Asn Lys Lys Lys 35 40 45 Asn Pro Glu Lys Pro His Phe Pro Leu Ala Thr Glu Asp Asp Val Arg 50 55 60 His His Phe Thr Pro Ser Glu Arg Gin Leu Cys Leu Ser Ser He Gin 65 70 75 80 Thr Ala Phe Asn Gin Gly Ala Gly Thr Cys Thr Leu Ser Asp Ser Gly 85 90 95 Arg He Ser Tyr Thr Val Glu Phe Ser Leu Pro Thr His His Thr Val 100 105 110 Arg Leu He Arg Val Thr Ala Ser Pro Ser Ala 115 120 (2) INFORMATION FOR SEQ ID NO:14: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 15101 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS : double (D) TOPOLOGY: unknown (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (vi) ORIGINAL SOURCE: (A) ORGANISM: Arteriviridae (B) STRAIN: VR-2332 (ix) FEATURE: (A) NAME/KEY: misc_feature (B) LOCATION: 7384..11775 (C) IDENTIFICATION METHOD: experimental (D) OTHER INFORMATION: /evidence- EXPERIMENTAL /label- ORFlb /citation- ( [1] ) (ix) FEATURE: (A) NAME/KEY: misc_feature (B) LOCATION: 11786..12535 (D) OTHER INFORMATION: /standard_name= "LV ORF 2" /citation- ( [1] ) (ix) FEATURE: (A) NAME/KEY: misc_feature (B) LOCATION: 212..7402 (D) OTHER INFORMATION: /standard_name= "LV ORF la" /citation- ( [1] ) (ix) FEATURE: (A) NAME/KEY: misc_feature (B) LOCATION: 12394..13191 (D) OTHER INFORMATION: /standard_name= "LV ORF 3" /citation- ( [1] ) (ix) FEATURE: (A) NAME/KEY: misc_feature B ) LOCATION: 12936..13487 (D) OTHER INFORMATION: /standard_name= "LV ORF 4" /citation- ( [1] ) (ix) FEATURE: (A) NAME/KEY: misc_feature (B) LOCATION: 13484..14089 (D) OTHER INFORMATION: /standard_name= "LV ORF 5" /citation- ( [1] ) (ix) FEATURE: (A) NAME/KEY: misc_feature (B) LOCATION: 14077..14598 (D) OTHER INFORMATION: /standard_name= "LV ORF 6" /citation- ( [1] ) (ix) FEATURE: (A) NAME/KEY: misc_feature (B) LOCATION: 14588..14974 (D) OTHER INFORMATION: /standard_name= "LV ORF 7" /citation- ( [1] ) (x) PUBLICATION INFORMATION: (A) AUTHORS: Meuienberg, J. J.M. Hulst, M. M. de Veijer, E. J. Moonen, P. L. den Besten, A. de Kluyver, E. P. Wensvoort, G. Moormann, R. J. (B) TITLE: Leiystad virus, the causative agent of procine epidemic abnortion and respiratory syndrome (PEARS) is related to LDV and EAV. (C) JOURNAL: Virology (D) VOLUME: 192 (F) PAGES: 62-72 (G) DATE: 1993 (K) RELEVANT RESIDUES IN SEQ ID NO:14: FROM 1 TO 15101 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:14: GGGTATTCCC CCTACATACA CGACACTTCT AGTGTTTGTG TACCTTGGAG GCGTGGGTAC 60 AGCCCCGCCC CACCCCTTGG CCCCTGTTCT AGCCCAACAG GTATCCTTCT CTCTCGGGGC 120 GAGTGCGCCG CCTGCTGCTC CCTTGCAGCG GGAAGGACCT CCCGAGTATT TCCGGAGAGC 180 ACCTGCTTTA CGGGATCTCC ACCCTTTAAC CATGTCTGGG ACGTTCTCCC GGTGCATGTG 240 CACCCCGGCT GCCCGGGTAT TTTGGAACGC CGGCCAAGTC TTTTGCACAC GGTGTCTCAG 300 TGCGCGGTCT CTTCTCTCTC CAGAGCTTCA GGACACTGAC CTCGGTGCAG TTGGCTTGTT 360 TTACAAGCCT AGGGACAAGC TTCACTGGAA AGTCCCTATC GGCATCCCTC AGGTGGAATG 420 TACTCCATCC GGGTGCTGTT GGCTCTCAGC TGTTTTCCCT TTGGCGCGTA TGACCTCCGG 480 CAATCACAAC TTCCTCCAAC GACTTGTGAA GGTTGCTGAT GTTTTGTACC GTGACGGTTG 540 CTTGGCACCT CGACACCTTC GTGAACTCCA AGTTTACGAG CGCGGCTGCA ACTGGTACCC 600 GATCACGGGG CCCGTGCCCG GGATGGGTTT GTTTGCGAAC TCCATGCACG TATCCGACCA 660 GCCGTTCCCT GGTGCCACCC ATGTGTTGAC TAACTCGCCT TTGCCTCAAC AGGCTTGTCG 720 GCAGCCGTTC TGTCCATTTG AGGAGGCTCA TTCTAGCGTG TACAGGTGGA AGAAATTTGT 780 GGTTTTCACG GACTCCTCCC TCAACGGTCG ATCTCGCATG ATGTGGACGC CGGAATCCGA 840 TGATTCAGCC GCCCTGGAGG TACTACCGCC TGAGTTAGAA CGTCAGGTCG AAATCCTCAT 900 TCGGAGTTTT CCTGCTCATC ACCCTGTCGA CCTGGCCGAC TGGGAGCTCA CTGAGTCCCC 960 TGAGAACGGT TTTTCCTTCA ACACGTCTCA TTCTTGCGGT CACCTTGTCC AGAACCCCGA 1020 CGTGTTTGAT GGCAAGTGCT GGCTCTCCTG CTTTTTGGGC CAGTCGGTCG AAGTGCGCTG 1080 CCATGAGGAA CATCTAGCTG ACGCCTTCGG TTACCAAACC AAGTGGGGCG TGCATGGTAA 1140 GTACCTCCAG CGCAGGCTTC AAGTTCGCGG CATTCGTGCT 3TAGTCGATC CTGATGGTCC 1200 CATTCACGTT GAAGCGCTGT CTTGCCCCCA GTCTTGGATC AGGCACCTGA CTCTGGATGA 1260 TGATGTCACC CCAGGATTCG TTCGCCTGAC ATCCCTTCGC ATTGTGCCGA ACACAGAGCC 1320 TACCACTTCC CGGATCTTTC GGTTTGGAGC GCATAAGTGG TATGGCGCTG CCGGCAAACG 1380 GGCTCGTGCT AAGCGTGCCG CTAAAAGTGA GAAGGATTCG GCTCCCACCC CCAAGGTTGC 1440 CCTGCCGGTC CCCACCTGTG GAATTACCAC CTACTCTCCA CCGACAGACG GGTCTTGTGG 1500 TTGGCATGTC CTTGCCGCCA TAATGAACCG GATGATAAAT GGTGACTTCA CGTCCCCTCT 1560 GACTCAGTAC AACAGACCAG AGGATGATTG GGCTTCTGAT TATGATCTTG TTCAGGCGAT 1620 TCAATGTCTA CGACTGCCTG CTACCGTGGT TCGGAATCGC GCCTGTCCTA ACGCCAAGTA 1680 CCTTATAAAA CTTAACGGAG TTCACTGGGA GGTAGAGGTG AGGTCTGGAA TGGCTCCTCG 1740 CTCCCTTTCT CGTGAATGTG TGGTTGGCGT TTGCTCTGAA GGCTGTGTCG CACCGCCTTA 1800 TCCAGCAGAC GGGCTACCTA AACGTGCACT CGAGGCCTTG GCGTCTGCTT ACAGACTACC 1860 CTCCGATTGT GTTAGCTCTG GTATTGCTGA CTTTCTTGCT AATCCACCTC CTCAGGAATT 1920 CTGGACCCTC GACAAAATGT TGACCTCCCC GTCACCAGAG CGGTCCGGCT TCTCTAGTTT 1980 GTATAAATTA CTATTAGAGG TTGTTCCGCA AAAATGCGGT GCCACGGAAG GGGCTTTCAT 2040 CTATGCTGTT GAGAGGATGT TGAAGGATTG TCCGAGCTCC AAACAGGCCA TGGCCCTTCT 2100 GGCAAAAATT AAAGTTCCAT CCTCAAAGGC CCCGTCTGTG TCCCTGGACG AGTGTTTCCC 2160 TACGGATGTT TTAGCCGACT TCGAGCCAGC ATCTCAGGAA AGGCCCCAAA GTTCCGGCGC 2220 TGCTGTTGTC CTGTGTTCAC CGGATGCAAA AGAGTTCGAG GAAGCAGCCC CGGAAGAAGT 2280 TCAAGAGAGT GGCCACAAGG CCGTCCACTC TGCACTCCTT GCCGAGGGTC CTAACAATGA 2340 GCAGGTACAG GTGGTTGCCG GTGAGCAACT GAAGCTCGGC GGTTGTGGTT TGGCAGTCGG 2400 GAATGCTCAT GAAGGTGCTC TGGTCTCAGC TGGTCTAATT AACCTGGTAG GCGGGAATTT 2460 GTCCCCCTCA GACCCCATGA AAGAAAACAT GCTCAATAGC CGGGAAGACG AACCACTGGA 2520 TTTGTCCCAA CCAGCACCAG CTTCCACAAC GACCCTTGTG AGAGAGCAAA CACCCGACAA 2580 CCCAGGTTCT GATGCCGGTG CCCTCCCCGT CACCGTTCGA GAATTTGTCC CGACGGGGCC 2640 TATACTCTGT CATGTTGAGC ACTGCGGCAC GGAGTCGGGC GACAGCAGTT CGCCTTTGGA 2700 TCTATCTGAT GCGCAAACCC TGGACCAGCC TTTAAATCTA TCCCTGGCCG CTTGGCCAGT 2760 GAGGGCCACC GCGTCTGACC CTGGCTGGGT CCACGGTAGG CGCGAGCCTG TCTTTGTAAA 2820 GCCTCGAAAT GCTTTCTCTG ATGGCGATTC AGCCCTTCAG TTCGGGGAGC TTTCTGAATC 2880 CAGCTCTGTC ATCGAGTTTG ACCGGACAAA AGATGCTCCG GTGGTTGACG CCCCTGTCGA 2940 CTTGACGACT TCGAACGAGG CCCTCTCTGT AGTCGATCCT TTCGAATTTG CCGAACTCAA 3000 GCGCCCGCGT TTCTCCGCAC AAGCCTTAAT TGACCGAGGC GGTCCACTTG CCGATGTCCA 3060 TGCAAAAATA AAGAACCGGG TATATGAACA GTGCCTCCAA GCTTGTGAGC CCGGTAGTCG 3120 TGCAACCCCA GCCACCAGGG AGTGGCTCGA CAAAATGTGG GATAGGGTGG ACATGAAAAC 3180 TTGGCGCTGC ACCTCGCAGT TCCAAGCTGG TCGCATTCTT GCGTCCCTCA AATTCCTCCC 3240 TGACATGATT CAAGACACAC CGCCTCCTGT TCCCAGGAAG AACCGAGCTA GTGACAATGC 3300 CGGCCTGAAG CAACTGGTGG CACAGTGGGA TAGGAAATTG AGTGTGACCC CCCCCCCAAA 3360 ACCGGTTGGG CCAGTGCTTG ACCAGATCGT CCCTCCGCCT ACGGATATCC AGCAAGAAGA 3420 TGTCACCCCC TCCGATGGGC CACCCCATGC GCCGGATTTT CCTAGTCGAG TGAGCACGGG 3480 CGGGAGTTGG AAAGGCCTTA TGCTTTCCGG CACCCGTCTC GCGGGGTCTA TCAGCCAGCG 3540 CCTTATGACA TGGGTTTTTG AAGTTTTCTC CCACCTCCCA GCTTTTATGC TCACACTTTT 3600 CTCGCCGCGG GGCTCTATGG CTCCAGGTGA TTGGTTGTTT GCAGGTGTCG TTTTACTTGC 3660 TCTCTTGCTC TGTCGTTCTT ACCCGATACT CGGATGCCTT CCCTTATTGG GTGTCTTTTC 3720 TGGTTCTTTG CGGCGTGTTC GTCTGGGTGT TTTTGGTTCT TGGATGGCTT TTGCTGTATT 3780 TTTATTCTCG ACTCCATCCA ACCCAGTCGG TTCTTCTTGT GACCACGATT CGCCGGAGTG 3840 TCATGCTGAG CTTTTGGCTC TTGAGCAGCG CCAACTTTGG GAACCTGTGC GCGGCCTTGT 3900 GGTCGGCCCC TCAGGCCTCT TATGTGTCAT TCTTGGCAAG TTACTCGGTG GGTCACGTTA 3960 TCTCTGGCAT GTTCTCCTAC GTTTATGCAT GCTTGCAGAT TTGGCCCTTT CTCTTGTTTA 4020 TGTGGTGTCC CAGGGGCGTT GTCACAAGTG TTGGGGAAAG TGTATAAGGA CAGCTCCTGC 4080 GGAGGTGGCT CTTAATGTAT TTCCTTTCTC GCGCGCCACC CGTGTCTCTC TTGTATCCTT 4140 GTGTGATCGA TTCCAAACGC CAAAAGGGGT TGATCCTGTG CACTTGGCAA CGGGTTGGCG 4200 CGGGTGCTGG CGTGGTGAGA GCCCCATCCA TCAACCACAC CAAAAGCCCA TAGCTTATGC 4260 CAATTTGGAT GAAAAGAAAA TGTCTGCCCA AACGGTGGTT GCTGTCCCAT ACGATCCCAG 4320 TCAGGCTATC AAATGCCTGA AAGTTCTGCA GGCGGGAGGG GCCATCGTGG ACCAGCCTAC 4380 ACCTGAGGTC GTTCGTGTGT CCGAGATCCC CTTCTCAGCC CCATTTTTCC CAAAAGTTCC 4440 AGTCAACCCA GATTGCAGGG TTGTGGTAGA TTCGGACACT TTTGTGGCTG CGGTTCGCTG 4500 CGGTTACTCG ACAGCACAAC TGGTTCTGGG CCGGGGCAAC TTTGCCAAGT TAAATCAGAC 4560 CCCCCCCAGG AACTCTATCT CCACCAAAAC GACTGGTGGG GCCTCTTACA CCCTTGCTGT 4620 GGCTCAAGTG TCTGCGTGGA CTCTTGTTCA TTTCATCCTC GGTCTTTGGT TCACATCACC 4680 TCAAGTGTGT GGCCGAGGAA CCGCTGACCC ATGGTGTTCA AATCCTTTTT CATATCCTAC 4740 CTATGGCCCC GGAGTTGTGT GCTCCTCTCG ACTTTGTGTG TCTGCCGACG GGGTCACCCT 4800 GCCATTGTTC TCAGCCGTGG CACAACTCTC CGGTAGAGAG GTGGGGATTT TTATTTTGGT 4860 GCTCGTCTCC TTGACTGCTT TGGCCCACCG CATGGCTCTT AAGGCAGACA TGTTAGTGGT 4920 CTTTTCGGCT TTTTGTGCTT ACGCCTGGCC CATGAGCTCC TGGTTAATCT GCTTCTTTCC 4980 TATACTCTTG AAGTGGGTTA CCCTTCACCC TCTTACTATG CTTTGGGTGC ACTCATTCTT 5040 GGTGTTTTGT CTGCCAGCAG CCGGCATCCT CTCACTAGGG ATAACTGGCC TTCTTTGGGC 5100 AATTGGCCGC TTTACCCAGG TTGCCGGAAT TATTACACCT TATGACATCC ACCAGTACAC 5160 CTCTGGGCCA CGTGGTGCAG CTGCTGTGGC CACAGCCCCA GAAGGCACTT ATATGGCCGC 5220 CGTCCGGAGA GCTGCTTTAA CTGGGCGAAC TTTAATCTTC ACCCCGTCTG CAGTTGGATC 5280 CCTTCTCGAA GGTGCTTTCA GGACTCATAA ACCCTGCCTT AACACCGTGA ATGTTGTAGG 5340 CTCTTCCCTT GGTTCCGGAG GGGTTTTCAC CATTGATGGC AGAAGAACTG TCGTCACTGC 5400 TGCCCATGTG TTGAACGGCG ACACAGCTAG AGTCACCGGC GACTCCTACA ACCGCATGCA 5460 CACTTTCAAG ACCAATGGTG ATTATGCCTG GTCCCATGCT GATGACTGGC AGGGCGTTGC 5520 CCCTGTGGTC AAGGTTGCGA AGGGGTACCG CGGTCGTGCC TACTGGCAAA CATCAACTGG 5580 TGTCGAACCC GGTATCATTG GGGAAGGGTT CGCCTTCTGT TTTACTAACT GCGGCGATTC 5640 GGGGTCACCC GTCATCTCAG AATCTGGTGA TCTTATTGGA ATCCACACCG GTTCAAACAA 5700 ACTTGGTTCT GGTCTTGTGA CAACCCCTGA AGGGGAGACC TGCACCATCA AAGAAACCAA 5760 GCTCTCTGAC CTTTCCAGAC ATTTTGCAGG CCCAAGCGTT CCTCTTGGGG ACATTAAATT 5820 GAGTCCGGCC ATCATCCCTG ATGTAACATC CATTCCGAGT GACTTGGCAT CGCTCCTAGC 5880 CTCCGTCCCT GTAGTGGAAG GCGGCCTCTC GACCGTTCAA CTTTTGTGTG TCTTTTTCCT 5940 TCTCTGGCGC ATGATGGGCC ATGCCTGGAC ACCCATTGTT GCCGTGGGCT TCTTTTTGCT 6000 GAATGAAATT CTTCCAGCAG TTTTGGTCCG AGCCGTGTTT TCTTTTGCAC TCTTTGTGCT 6060 TGCATGGGCC ACCCCCTGGT CTGCACAGGT GTTGATGATT AGACTCCTCA CGGCATCTCT 6120 CAACCGCAAC AAGCTTTCTC TGGCGTTCTA CGCACTCGGG GGTGTCGTCG GTTTGGCAGC 6180 TGAAATCGGG ACTTTTGCTG GCAGATTGTC TGAATTGTCT CAAGCTCTTT CGACATACTG 6240 CTTCTTACCT AGGGTCCTTG CTATGACCAG TTGTGTTCCC ACCATCATCA TTGGTGGACT 6300 CCATACCCTC GGTGTGATTC TGTGGTTATT CAAATACCGG TGCCTCCACA ACATGCTGGT 6360 TGGTGATGGG AGTTTTTCAA GCGCCTTCTT CCTACGGTAT TTTGCAGAGG GTAATCTCAG 6420 AAAAGGTGTT TCACAGTCCT GTGGCATGAA TAACGAGTCC CTAACGGCTG CTTTAGCTTG 6480 CAAGTTGTCA CAGGCTGACC TTGATTTTTT GTCCAGCTTA ACGAACTTCA AGTGCTTTGT 6540 ATCTGCTTCA AACATGAAAA ATGCTGCCGG CCAGTACATT GAAGCAGCGT ATGCCAAGGC 6600 CCTGCGCCAA GAGTTGGCCT CTCTAGTTCA GATTGACAAA ATGAAAGGAG TTTTGTCCAA 6660 GCTCGAGGCC TTTGCTGAAA CAGCCACCCC GTCCCTTGAC ATAGGTGACG TGATTGTTCT 6720 GCTTGGGCAA CATCCTCACG GATCCATCCT CGATATTAAT G.GGGGACTG AAAGGAAAAC 6780 TGTGTCCGTG CAAGAGACCC GGAGCCTAGG CGGCTCCAAA TTCAGTGTTT GTACTGTCGT 6840 GTCCAACACA CCCGTGGACG CCTTGACCGG CATCCCACTC CAGACACCAA CCCCTCTTTT 6900 TGAGAATGGT CCGCGTCATC GCAGCGAGGA AGACGATCTT AAAGTCGAGA GGATGAAGAA 6960 ACACTGTGTA TCCCTCGGCT TCCACAACAT CAATGGCAAA GTTTACTGCA AAATTTGGGA 7020 CAAGTCTACC GGTGACACCT TTTACACGGA TGATTCCCGG TACACCCAAG ACCATGCTTT 7080 TCAGGACAGG TCAGCCGACT ACAGAGACAG GGACTATGAG GGTGTGCAAA CCACCCCCCA 7140 ACAGGGATTT GATCCAAAGT CTGAAACCCC TGTTGGCACT GTTGTGATCG GCGGTATTAC 7200 GTATAACAGG TATCTGATCA AAGGTAAGGA GGTTCTGGTC CCCAAGCCTG ACAACTGCCT 7260 TGAAGCTGCC AAGCTGTCCC TTGAGCAAGC TCTCGCTGGG ATGGGCCAAA CTTGCGACCT 7320 TACAGCTGCC GAGGTGGAAA AGCTAAAGCG CATCATTAGT CAACTCCAAG GTTTGACCAC 7380 TGAACAGGCT TTAAACTGTT AGCCGCCAGC GGCTTGACCC GCTGTGGCCG CGGCGGCCTA 7440 GTTGTGACTG AAACGGCGGT AAAAATTATA AAATACCACA GCAGAACTTT CACCTTAGGC 7500 CCTTTAGACC TAAAAGTCAC TTCCGAGGTG GAGGTAAAGA AATCAACTGA GCAGGGCCAC 7560 GCTGTTGTGG CAAACTTATG TTCCGGTGTC ATCTTGATGA GACCTCACCC ACCGTCCCTT 7620 GTCGACGTTC TTCTGAAACC CGGACTTGAC ACAATACCCG GCATTCAACC AGGGCATGGG 7680 GCCGGGAATA TGGGCGTGGA CGGTTCTATT TGGGATTTTG AAACCGCACC CACAAAGGCA 7740 GAACTCGAGT TATCCAAGCA AATAATCCAA GCATGTGAAG TTAGGCGCGG GGACGCCCCG 7800 AACCTCCAAC TCCCTTACAA GCTCTATCCT GTTAGGGGGG ATCCTGAGCG GCATAAAGGC 7860 CGCCTTATCA ATACCAGGTT TGGAGATTTA CCTTACAAAA CTCCTCAAGA CACCAAGTCC 7920 GCAATCCACG CGGCTTGTTG CCTGCACCCC AACGGGGCCC CCGTGTCTGA TGGTAAATCC 7980 ACACTAGGTA CCACTCTTCA ACATGGTTTC GAGCTTTATG TCCCTACTGT GCCCTATAGT 8040 GTCATGGAGT ACCTTGATTC ACGCCCTGAC ACCCCTTTTA TGTGTACTAA ACATGGCACT 8100 TCCAAGGCTG CTGCAGAGGA CCTCCAAAAA TACGACCTAT CCACCCAAGG ATTTGTCCTG 8160 CCTGGGGTCC TACGCCTAGT ACGCAGATTC ATCTTTGGCC ATATTGGTAA GGCGCCGCCA 8220 TTGTTCCTCC CATCAACCTA TCCCGCCAAG AACTCTATGG CAGGGATCAA TGGCCAGAGG 8280 TTCCCAACAA AGGACGTTCA GAGCATACCT GAAATTGATG AAATGTGTGC CCGCGCTGTC 8340 AAGGAGAATT GGCAAACTGT GACACCTTGC ACCCTCAAGA AACAGTACTG TTCCAAGCCC 8400 AAAACCAGGA CCATCCTGGG CACCAACAAC TTTATTGCCT TGGCTCACAG ATCGGCGCTC 8460 AGTGGTGTCA CCCAGGCATT CATGAAGAAG GCTTGGAAGT CCCCAATTGC CTTGGGGAAA 8520 AACAAATTCA AGGAGCTGCA TTGCACTGTC GCCGGCAGGT GTCTTGAGGC CGACTTGGCC 8580 TCCTGTGACC GCAGCACCCC CGCCATTGTA AGATGGTTTG TTGCCAACCT CCTGTATGAA 8640 CTTGCAGGAT GTGAAGAGTA CTTGCCTAGC TATGTGCTTA ATTGCTGCCA TGACCTCGTG 8700 GCAACACAGG ATGGTGCCTT CACAAAACGC GGTGGCCTGT CGTCCGGGGA CCCCGTCACC 8760 AGTGTGTCCA ACACCGTATA TTCACTGGTA ATTTATGCCC AGCACATGGT ATTGTCGGCC 8820 TTGAAAATGG GTCATGAAAT TGGTCTTAAG TTCCTCGAGG AACAGCTCAA GTTCGAGGAC 8880 CTCCTTGAAA TTCAGCCTAT GTTGGTATAC TCTGATGATC TTGTCTTGTA CGCTGAAAGA 8940 CCCACATTTC CCAATTACCA CTGGTGGGTC GAGCACCTTG ACCTGATGCT GGGTTTCAGA 9000 ACGGACCCAA AGAAAACCGT CATAACTGAT AAACCCAGCT TCCTCGGCTG CAGAATTGAG 9060 GCAGGGCGAC AGCTAGTCCC CAATCGCGAC CGCATCCTGG CTGCTCTTGC ATATCACATG 9120 AAGGCGCAGA ACGCCTCAGA GTATTATGCG TCTGCTGCCG CAATCCTGAT GGATTCATGT 9180 GCTTGCATTG ACCATGACCC TGAGTGGTAT GAGGACCTCA TCTGCGGTAT TGCCCGGTGC 9240 GCCCGCCAGG ATGGTTATAG CTTCCCAGGT CCGGCATTTT TCATGTCCAT GTGGGAGAAG 9300 CTGAGAAGTC ATAATGAAGG GAAGAAATTC CGCCACTGCG GCATCTGCGA CGCCAAAGCC 9360 GACTATGCGT CCGCCTGTGG GCTTGATTTG TGTTTGTTCC ATTCGCACTT TCATCAACAC 9420 TGCCCTGTCA CTCTGAGCTG CGGTCACCAT GCCGGTTCAA AGGAATGTTC GCAGTGTCAG 9480 TCACCTGTTG GGGCTGGCAG ATCCCCTCTT GATGCCGTGC TAAAACAAAT TCCATACAAA 9540 CCTCCTCGTA CTGTCATCAT GAAGGTGGGT AATAAAACAA CGGCCCTCGA TCCGGGGAGG 9600 TACCAGTCCC GTCGAGGTCT CGTTGCAGTC AAGAGGGGTA TTGCAGGCAA TGAAGTTGAT 9660 CTTTCTGATG GGGACTACCA AGTGGTGCCT CTTTTGCCGA CTTGCAAAGA CATAAACATG 9720 GTGAAGGTGG CTTGCAATGT ACTACTCAGC AAGTTCATAG TAGGGCCACC AGGTTCCGGA 9780 AAGACCACCT GGCTACTGAG TCAAGTCCAG GACGATGATG TCATTTACAC ACCCACCCAT 9840 CAGACTATGT TTGATATAGT CAGTGCTCTC AAAGTTTGCA GGTATTCCAT TCCAGGAGCC 9900 TCAGGACTCC CTTTCCCACC ACCTGCCAGG TCCGGGCCGT GGGTTAGGCT TATTGCCAGC 9960 GGGCACGTCC CTGGCCGAGT ATCATACCTC GATGAGGCTG GATATTGTAA TCATCTGGAC 10020 ATTCTTAGAC TGCTTTCCAA AACACCCCTT GTGTGTTTGG GTGACCTTCA GCAACTTCAC 10080 CCTGTCGGCT TTGATTCCTA CTGTTATGTG TTCGATCAGA TGCCTCAGAA GCAGCTGACC 10140 ACTATTTACA GATTTGGCCC TAACATCTGC GCACGCATCC AGCCTTGTTA CAGGGAGAAA 10200 CTTGAATCTA AGGCTAGGAA CACTAGGGTG GTTTTTACCA CCCGGCCTGT GGCCTTTGGT 10260 CAGGTGCTGA CACCATACCA TAAAGATCGC ATCGGCTCTG CGATAACCAT AGATTCATCC 10320 CAGGGGGCCA CCTTTGATAT TGTGACATTG CATCTACCAT CGCCAAAGTC CCTAAATAAA 10380 TCCCGAGCAC TTGTAGCCAT CACTCGGGCA AGACACGGGT TGTTCATTTA TGACCCTCAT 10440 AACCAGCTCC AGGAGTTTTT CAACTTAACC CCTGAGCGCA CTGATTGTAA CCTTGTGTTC 10500 AGCCGTGGGG ATGAGCTGGT AGTTCTGAAT GCGGATAATG CAGTCACAAC TGTAGCGAAG 10560 GCCCTTGAGA CAGGTCCATC TCGATTTCGA GTATCAGACC CGAGGTGCAA GTCTCTCTTA 10620 GCCGCTTGTT CGGCCAGTCT GGAAGGGAGC TGTATGCCAC TACCGCAAGT GGCACATAAC 10680 CTGGGGTTTT ACTTTTCCCC GGACAGTCCA ACATTTGCAC CTCTGCCAAA AGAGTTGGCG 10740 CCACATTGGC CAGTGGTTAC CCACCAGAAT AATCGGGCGT GGCCTGATCG ACTTGTCGCT 10800 AGTATGCGCC CAATTGATGC CCGCTACAGC AAGCCAATGG TCGGTGCAGG GTATGTGGTC 10860 GGGCCGTCCA CCTTTCTTGG TACTCCTGGT GTGGTGTCAT ACTATCTCAC ACTATACATC 10920 AGGGGTGAGC CCCAGGCCTT GCCAGAAACA CTCGTTTCAA CAGGGCGTAT AGCCACAGAT 10980 TGTCGGGAGT ATCTCGACGC GGCTGAGGAA GAGGCAGCAA AAGAACTCCC CCACGCATTC 11040 ATTGGCGATG TCAAAGGTAC CACGGTTGGG GGGTGTCATC ACATTACATC AAAATACCTA 11100 CCTAGGTCCC TGCCTAAGGA CTCTGTTGCC GTAGTTGGAG TAAGTTCGCC CGGCAGGGCT 11160 GCTAAAGCCG TGTGCACTCT CACCGATGTG TACCTCCCCG AACTCCGGCC ATATCTGCAA 11220 CCTGAGACGG CATCAAAATG CTGGAAACTC AAATTAGACT TCAGGGACGT CCGACTAATG 11280 GTCTGGAAAG GAGCCACCGC CTATTTCCAG TTGGAAGGGC TTACATGGTC GGCGCTGCCC 11340 GACTATGCCA GGTTTATTCA GCTGCCCAAG GATGCCGTTG TATACATTGA TCCGTGTATA 11400 GGACCGGCAA CAGCCAACCG TAAGGTCGTG CGAACCACAG ACTGGCGGGC CGACCTGGCA 11460 GTGACACCGT ATGATTACGG TGCCCAGAAC ATTTTGACAA CAGCCTGGTT CGAGGACCTC 11520 GGGCCGCAGT GGAAGATTTT GGGGTTGCAG CCCTTTAGGC GAGCATTTGG CTTTGAAAAC 11580 ACTGAGGATT GGGCAATCCT TGCACGCCGT ATGAATGACG GCAAGGACTA CACTGACTAT 11640 AACTGGAACT GTGTTCGAGA ACGCCCACAC GCCATCTACG GGCGTGCTCG TGACCATACG 11700 TATCATTTTG CCCCTGGCAC AGAATTGCAG GTAGAGCTAG GTAAACCCCG GCTGCCGCCT 11760 GGGCAAGTGC CGTGAATTCG GGGTGATGCA ATGGGGTCAC TGTGGAGTAA AATCAGCCAG 11820 CTGTTCGTGG ACGCCTTCAC TGAGTTCCTT GTTAGTGTGG TTGATATTGC CATTTTCCTT 11880 GCCATACTGT TTGGGTTCAC CGTCGCAGGA TGGTTACTGG TCTTTCTTCT CAGAGTGGTT 11940 TGCTCCGCGC TTCTCCGTTC GCGCTCTGCC ATTCACTCTC CCGAACTATC GAAGGTCCTA 12000 TGAAGGCTTG TTGCCCAACT GCAGACCGGA TGTCCCACAA TTTGCAGTCA AGCACCCATT 12060 GGGTATGTTT TGGCACATGC GAGTTTCCCA CTTGATTGAT GAGATGGTCT CTCGTCGCAT 12120 TTACCAGACC ATGGAACATT CAGGTCAAGC GGCCTGGAAG CAGGTGGTTG GTGAGGCCAC 12180 TCTCACGAAG CTGTCAGGGC TCGATATAGT TACTCATTTC CAACACCTGG CCGCAGTGGA 12240 GGCGGATTCT TGCCGCTTTC TCAGCTCACG ACTCGTGATG CTAAAAAATC TTGCCGTTGG 12300 CAATGTGAGC CTACAGTACA ACACCACGTT GGACCGCGTT GAGCTCATCT TCCCCACGCC 12360 AGGTACGAGG CCCAAGTTGA CCGATTTCAG ACAATGGCTC ATCAGTGTGC ACGCTTCCAT 12420 TTTTTCCTCT GTGGCTTCAT CTGTTACCTT GTTCATAGTG CTTTGGCTTC GAATTCCAGC 12480 TCTACGCTAT GTTTTTGGTT TCCATTGGCC CACGGCAACA CATCATTCGA GCTGACCATC 12540 AACTACACCA TATGCATGCC CTGTTCTACC AGTCAAGCGG CTCGCCAAAG GCTCGAGCCC 12600 GGTCGTAACA TGTGGTGCAA AATAGGGCAT GACAGGTGTG AGGAGCGTGA CCATGATGAG 12660 TTGTTAATGT CCATCCCGTC CGGGTACGAC AACCTCAAAC TTGAGGGTTA TTATGCTTGG 12720 CTGGCTTTTT TGTCCTTTTC CTACGCGGCC CAATTCCATC CGGAGTTGTT CGGGATAGGG 12780 AATGTGTCGC GCGTCTTCGT GGACAAGCGA CACCAGTTCA TTTGTGCCGA GCATGATGGA 12840 CACAATTCAA CCGTATCTAC CGGACACAAC ATCTCCGCAT TATATGCGGC ATATTACCAC 12900 CACCAAATAG ACGGGGGCAA TTGGTTCCAT TTGGAATGGC TGCGGCCACT CTTTTCTTCC 12960 TGGCTGGTGC TCAACATATC ATGGTTTCTG AGGCGTTCGC CTGTAAGCCC TGTTTCTCGA 13020 CGCATCTATC AGATATTGAG ACCAACACGA CCGCGGCTGC CGGTTTCATG GTCCTTCAGG 13080 ACATCAATTG TTTCCGACCT CACGGGGTCT CAGCAGCGCA AGAGAAAATT TCCTTCGGAA 13140 AGTCGTCCCA ATGTCGTGAA GCCGTCGGTA CTCCCCAGTA CATCACGATA ACGGCTAACG 13200 TGACCGACGA ATCATACTTG TACAACGCGG ACCTGCTGAT GCTTTCTGCG TGCCTTTTCT 13260 ACGCCTCAGA AATGAGCGAG AAAGGCTTCA AAGTCATCTT TGGGAATGTC TCTGGCGTTG 13320 TTTCTGCTTG TGTCAATTTC ACAGATTATG TGGCCCATGT GACCCAACAT ACCCAGCAGC 13380 ATCATCTGGT AATTGATCAC ATTCGGTTGC TGCATTTCCT GACACCATCT GCAATGAGGT 13440 GGGCTACAAC CATTGCTTGT TTGTTCGCCA TTCTCTTGGC AATATGAGAT GTTCTCACAA 13500 ATTGGGGCGT TTCTTGACTC CGCACTCTTG CTTCTGGTGG CTTTTTTTGC TGTGTACCGG 13560 CTTGTCCTGG TCCTTTGCCG ATGGCAACGG CGACAGCTCG ACATACCAAT ACATATATAA 13620 CTTGACGATA TGCGAGCTGA ATGGGACCGA CTGGTTGTCC AGCCATTTTG GTTGGGCAGT 13680 CGAGACCTTT GTGCTTTACC CGGTTGCCAC TCATATCCTC TCACTGGGTT TTCTCACAAC 13740 AAGCCATTTT TTTGACGCGC TCGGTCTCGG CGCTGTATCC ACTGCAGGAT TTGTTGGCGG 13800 GCGGTACGTA CTCTGCAGCG TCTACGGCGC TTGTGCTTTC GCAGCGTTCG TATGTTTTGT 13860 CATCCGTGCT GCTAAAAATT GCATGGCCTG CCGCTATGCC CGTACCCGGT TTACCAACTT 13920 CATTGTGGAC GACCGGGGGA GAGTTCATCG ATGGAAGTCT CCAATAGTGG TAGAAAAATT 13980 GGGCAAAGCC GAAGTCGATG GCAACCTCGT CACCATCAAA CATGTCGTCC TCGAAGGGGT 14040 TAAAGCTCAA CCCTTGACGA GGACTTCGGC TGAGCAATGG GAGGCCTAGA CGATTTTTGC 14100 AACGATCCTA TCGCCGCACA AAAGCTCGTG CTAGCCTTTA GCATCACATA CACACCTATA 14160 ATGATATACG CCCTTAAGGT GTCACGCGGC CGACTCCTGG GGCTGTTGCA CATCCTAATA 14220 TTTCTGAACT GTTCCTTTAC ATTCGGATAC ATGACATATG TGCATTTTCA ATCCACCAAC 14280 CGTGTCGCAC TTACCCTGGG GGCTGTTGTC GCCCTTCTGT GGGGTGTTTA CAGCTTCACA 14340 GAGTCATGGA AGTTTATCAC TTCCAGATGC AGATTGTGTT GCCTTGGCCG GCGATACATT 14400 CTGGCCCCTG CCCATCACGT AGAAAGTGCT GCAGGTCTCC ATTCAATCTC AGCGTCTGGT 14460 AACCGAGCAT ACGCTGTGAG AAAGCCCGGA CTAACATCAG TGAACGGCAC TCTAGTACCA 14520 GGACTTCGGA GCCTCGTGCT GGGCGGCAAA CGAGCTGTTA AACGAGGAGT GGTTAACCTC 14580 GTCAAGTATG GCCGGTAAAA ACCAGAGCCA GAAGAAAAAG AAAAGTACAG CTCCGATGGG 14640 GAATGGCCAG CCAGTCAATC AACTGTGCCA GTTGCTGGGT GCAATGATAA AGTCCCAGCG 14700 CCAGCAACCT AGGGGAGGAC AGGCCAAAAA GAAAAAGCCT GAGAAGCCAC ATTTTCCCCT 14760 GGCTGCTGAA GATGACATCC GGCACCACCT CACCCAGACT GAACGCTCCC TCTGCTTGCA 14820 ATCGATCCAG ACGGCTTTCA ATCAAGGCGC AGGAACTGCG TCGCTTTCAT CCAGCGGGAA 14880 GGTCAGTTTT CAGGTTGAGT TTATGCTGCC GGTTGCTCAT ACAGTGCGCC TGATTCGCGT 14940 GACTTCTACA TCCGCCAGTC AGGGTGCAAG TTAATTTGAC AGTCAGGTGA ATGGCCGCGA 15000 TTGGCGTGTG GCCTCTGAGT CACCTATTCA ATTAGGGCGA TCACATGGGG GTCATACTTA 15060 ATCAGGCAGG AACCATGTGA CCGAAATTAA AAAAAAAAAA A 15101 (2) INFORMATION FOR SEQ ID NO:15: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 747 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 1..747 (D) OTHER INFORMATION: /standard name- "LV ORF 2" ( i) SEQUENCE DESCRIPTION: SEQ ID NO:15: ATG CAA TGG GGT CAC TGT GGA GTA AAA TCA GCC AGC TGT TCG TGG ACG 48 Met Gin Trp Gly His Cys Gly Val Lys Ser Ala Ser Cys Ser Trp Thr 1 5 10 15 CCT TCA CTG AGT TCC TTG TTA GTG TGG TTG ATA TTG CCA TTT TCC TTG 96 Pro Ser Leu Ser Ser Leu Leu Val Trp Leu He Leu Pro Phe Ser Leu 20 25 30 CCA TAC TGT TTG GGT TCA CCG TCG CAG GAT GGT TAC TGG TCT TTC TTC 144 Pro Tyr Cys Leu Gly Ser Pro Ser Gin Asp Gly Tyr Trp Ser Phe Phe 35 40 45 TCA GAG TGG TTT GCT CCG CGC TTC TCC GTT CGC GCT CTG CCA TTC ACT 192 Ser Glu Trp Phe Ala Pro Arg Phe Ser Val Arg Ala Leu Pro Phe Thr 50 55 60 CTC CCG AAC TAT CGA AGG TCC TAT GAA GGC TTG TTG CCC AAC TGC AGA 240 Leu Pro Asn Tyr Arg Arg Ser Tyr Glu Gly Leu Leu Pro Asn Cys Arg 65 70 75 80 CCG GAT GTC CCA CAA TTT GCA GTC AAG CAC CCA TTG GGT ATG TTT TGG 288 Pro Asp Val Pro Gin Phe Ala Val Lys His Pro Leu Gly Met Phe Trp 85 90 95 CAC ATG CGA GTT TCC CAC TTG ATT GAT GAG ATG GTC TCT CGT CGC ATT 336 His Met Arg Val Ser His Leu He Asp Glu Met Val Ser Arg Arg He 100 105 110 TAC CAG ACC ATG GAA CAT TCA GGT CAA GCG GCC TGG AAG CAG GTG GTT 384 Tyr Gin Thr Met Glu His Ser Gly Gin Ala Ala Trp Lys Gin Val Val 115 120 125 GGT GAG GCC ACT CTC ACG AAG CTG TCA GGG CTC GAT ATA GTT ACT CAT 432 Gly Glu Ala Thr Leu Thr Lys Leu Ser Gly Leu Asp He Val Thr His 130 135 140 TTC CAA CAC CTG GCC GCA GTG GAG GCG GAT TCT TGC CGC TTT CTC AGC 480 Phe Gin His Leu Ala Ala Val Glu Ala Asp Ser Cys Arg Phe Leu Ser 145 150 155 160 TCA CGA CTC GTG ATG CTA AAA AAT CTT GCC GTT GGC AAT GTG AGC CTA 528 Ser Arg Leu Val Met Leu Lys Asn Leu Ala Val Gly Asn Val Ser Leu 165 170 175 CAG TAC AAC ACC ACG TTG GAC CGC GTT GAG CTC ATC TTC CCC ACG CCA 576 Gin Tyr Asn Thr Thr Leu Asp Arg Val Glu Leu He Phe Pro Thr Pro 180 185 190 GGT ACG AGG CCC AAG TTG ACC GAT TTC AGA CAA TGG CTC ATC AGT GTG 624 Gly Thr Arg Pro Lys Leu Thr Asp Phe Arg Gin Trp Leu He Ser Val 195 200 205 CAC GCT TCC ATT TTT TCC TCT GTG GCT TCA TCT GTT ACC TTG TTC ATA 672 His Ala Ser He Phe Ser Ser Val Ala Ser Ser Val Thr Leu Phe He 210 215 220 GTG CTT TGG CTT CGA ATT CCA GCT CTA CGC TAT GTT TTT GGT TTC CAT 720 Val Leu Trp Leu Arg He Pro Ala Leu Arg Tyr Val Phe Gly Phe His 225 230 235 240 TGG CCC ACG GCA ACA CAT CAT TCG AGC 747 Trp Pro Thr Ala Thr His His Ser Ser 245 (2) INFORMATION FOR SEQ ID NO:16: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 249 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:lό: Met Gin Trp Gly His Cys Gly Val Lys Ser Ala Ser Cys Ser Trp Thr 1 5 10 15 Pro Ser Leu Ser Ser Leu Leu Val Trp Leu He Leu Pro Phe Ser Leu 20 25 30 Pro Tyr Cys Leu Gly Ser Pro Ser Gin Asp Gly Tyr Trp Ser Phe Phe 35 40 45 Ser Glu Trp Phe Ala Pro Arg Phe Ser Val Arg Ala Leu Pro Phe Thr 50 55 60 Leu Pro Asn Tyr Arg Arg Ser Tyr Glu Gly Leu Leu Pro Asn Cys Arg 65 70 75 80 Pro Asp Val Pro Gin Phe Ala Val Lys His Pro Leu Gly Met Phe Trp 85 90 95 His Met Arg Val Ser His Leu He Asp Glu Met Val Ser.Arg Arg He 100 105 110 Tyr Gin Thr Met Glu His Ser Gly Gin Ala Ala Trp Lys Gin Val Val 115 120 125 Gly Glu Ala Thr Leu Thr Lys Leu Ser Gly Leu Asp He Val Thr His 130 135 140 Phe Gin His Leu Ala Ala Val Glu Ala Asp Ser Cys Arg Phe Leu Ser 145 150 155 160 Ser Arg Leu Val Met Leu Lys Asn Leu Ala Val Gly Asn Val Ser Leu 165 170 175 Gln Tyr Asn Thr Thr Leu Asp Arg Val Glu Leu He Phe Pro Thr Pro 180 185 190 Gly Thr Arg Pro Lys Leu Thr Asp Phe Arg Gin Trp Leu He Ser Val 195 200 205 His Ala Ser He Phe Ser Ser Val Ala Ser Ser Val Thr Leu Phe He 210 215 220 Val Leu Trp Leu Arg He Pro Ala Leu Arg Tyr Val Phe Gly Phe His 225 230 235 240 Trp Pro Thr Ala Thr His His Ser Ser 245 (2) INFORMATION FOR SEQ ID NO:17: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 795 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 1..795 (D) OTHER INFORMATION: /standard name- "LV ORF 3" (xi) SEQUENCE DESCRIPTION: SEQ ID NO:17: ATG GCT CAT CAG TGT GCA CGC TTC CAT TTT TTC CTC TGT GGC TTC ATC 48 Met Ala His Gin Cys Ala Arg Phe His Phe Phe Leu Cys Gly Phe He 1 5 10 15 TGT TAC CTT GTT CAT AGT GCT TTG GCT TCG AAT TCC AGC TCT ACG CTA 96 Cys Tyr Leu Val His Ser Ala Leu Ala Ser Asn Ser Ser Ser Thr Leu 20 25 30 TGT TTT TGG TTT CCA TTG GCC CAC GGC AAC ACA TCA TTC GAG CTG ACC 144 Cys Phe Trp Phe Pro Leu Ala His Gly Asn Thr Ser Phe Glu Leu Thr 35 40 45 ATC AAC TAC ACC ATA TGC ATG CCC TGT TCT ACC AGT CAA GCG GCT CGC 192 He Asn Tyr Thr He Cys Met Pro Cys Ser Thr Ser Gin Ala Ala Arg 50 55 60 CAA AGG CTC GAG CCC GGT CGT AAC ATG TGG TGC AAA ATA GGG CAT GAC 240 Gin Arg Leu Glu Pro Gly Arg Asn Met Trp Cys Lys He Gly His Asp 65 70 75 80 AGG TGT GAG GAG CGT GAC CAT GAT GAG TTG TTA ATG TCC ATC CCG TCC 288 Arg Cys Glu Glu Arg Asp His Asp Glu Leu Leu Met Ser He Pro Ser 85 90 95 GGG TAC GAC AAC CTC AAA CTT GAG GGT TAT TAT GCT TGG CTG GCT TTT 336 Gly Tyr Asp Asn Leu Lys Leu Glu Gly Tyr Tyr Ala Trp Leu Ala Phe 100 105 110 TTG TCC TTT TCC TAC GCG GCC CAA TTC CAT CCG GAG TTG TTC GGG ATA 384 Leu Ser Phe Ser Tyr Ala Ala Gin Phe His Pro Glu Leu Phe Gly He 115 120 125 GGG AAT GTG TCG CGC GTC TTC GTG GAC AAG CGA CAC CAG TTC ATT TGT 432 Gly Asn Val Ser Arg Val Phe Val Asp Lys Arg His Gin Phe He Cys 130 135 140 GCC GAG CAT GAT GGA CAC AAT TCA ACC GTA TCT ACC GGA CAC AAC ATC 480 Ala Glu His Asp Gly His Asn Ser Thr Val Ser Thr Gly His Asn He 145 150 155 160 TCC GCA TTA TAT GCG GCA TAT TAC CAC CAC CAA ATA GAC GGG GGC AAT 528 Ser Ala Leu Tyr Ala Ala Tyr Tyr His His Gin He Asp Gly Gly Asn 165 170 175 TGG TTC CAT TTG GAA TGG CTG CGG CCA CTC TTT TCT TCC TGG CTG GTG 576 Trp Phe His Leu Glu Trp Leu Arg Pro Leu Phe Ser Ser Trp Leu Val 180 185 190 CTC AAC ATA TCA TGG TTT CTG AGG CGT TCG CCT GTA AGC CCT GTT TCT 624 Leu Asn He Ser Trp Phe Leu Arg Arg Ser Pro Val Ser Pro Val Ser 195 200 205 CGA CGC ATC TAT CAG ATA TTG AGA CCA ACA CGA CCG CGG CTG CCG GTT 672 Arg Arg He Tyr Gin He Leu Arg Pro Thr Arg Pro Arg Leu Pro Val 210 215 220 TCA TGG TCC TTC AGG ACA TCA ATT GTT TCC GAC CTC ACG GGG TCT CAG 720 Ser Trp Ser Phe Arg Thr Ser He Val Ser Asp Leu Thr Gly Ser Gin 225 230 235 240 CAG CGC AAG AGA AAA TTT CCT TCG GAA AGT CGT CCC AAT GTC GTG AAG 768 Gin Arg Lys Arg Lys Phe Pro Ser Glu Ser Arg Pro Asn Val Val Lys 245 250 255 CCG TCG GTA CTC CCC AGT ACA TCA CGA 95 Pro Ser Val Leu Pro Ser Thr Ser Arg 260 265 (2) INFORMATION FOR SEQ ID NO-.18: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 265 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:18: Met Ala His Gin Cys Ala Arg Phe His Phe Phe Leu Cys Gly Phe He 1 5 10 15 Cys Tyr Leu Val His Ser Ala Leu Ala Ser Asn Ser Ser Ser Thr Leu 20 25 30 Cys Phe Trp Phe Pro Leu Ala His Gly Asn Thr Ser Phe Glu Leu Thr 35 40 45 He Asn Tyr Thr He Cys Met Pro Cys Ser Thr Ser Gin Ala Ala Arg 50 55 60 Gin Arg Leu Glu Pro Gly Arg Asn Met Trp Cys Lys He Gly His Asp 65 70 75 80 Arg Cys Glu Glu Arg Asp His Asp Glu Leu Leu Met Ser He Pro Ser 85 90 95 Gly Tyr Asp Asn Leu Lys Leu Glu Gly Tyr Tyr Ala Trp Leu Ala Phe 100 105 110 Leu Ser Phe Ser Tyr Ala Ala Gin Phe His Pro Glu Leu Phe Gly He 115 120 125 Gly Asn Val Ser Arg Val Phe Val Asp Lys Arg His Gin Phe He Cys 130 135 140 Ala Glu His Asp Gly His Asn Ser Thr Val Ser Thr Gly His Asn He 145 150 155 160 Ser Ala Leu Tyr Ala Ala Tyr Tyr His His Gin He Asp Gly Gly Asn 165 170 175 Trp Phe His Leu Glu Trp Leu Arg Pro Leu Phe Ser Ser Trp Leu Val 180 185 190 Leu Asn He Ser Trp Phe Leu Arg Arg Ser Pro Val Ser Pro Val Ser 195 200 205 Arg Arg He Tyr Gin He Leu Arg Pro Thr Arg Pro Arg Leu Pro Val 210 215 220 Ser Trp Ser Phe Arg Thr Ser He Val Ser Asp Leu Thr Gly Ser Gin 225 230 235 240 Gin Arg Lys Arg Lys Phe Pro Ser Glu Ser Arg Pro Asn Val Val Lys 245 250 255 Pro Ser Val Leu Pro Ser Thr Ser Arg 260 265 (2) INFORMATION FOR SEQ ID NO:19: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 549 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS : double (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 1..549 (D) OTHER INFORMATION: /standard name- "LV ORF 4" (xi) SEQUENCE DESCRIPTION: SEQ ID NO:19: ATG GCT GCG GCC ACT CTT TTC TTC CTG GCT GGT GCT CAA CAT ATC ATG 48 Met Ala Ala Ala Thr Leu Phe Phe Leu Ala Gly Ala Gin His He Met 1 5 10 15 GTT TCT GAG GCG TTC GCC TGT AAG CCC TGT TTC TCG ACG CAT CTA TCA 96 Val Ser Glu Ala Phe Ala Cys Lys Pro Cys Phe Ser Thr His Leu Ser 20 25 30 GAT ATT GAG ACC AAC ACG ACC GCG GCT GCC GGT TTC ATG GTC CTT CAG 144 Asp He Glu Thr Asn Thr Thr Ala Ala Ala Gly Phe Met Val Leu Gin 35 40 45 GAC ATC AAT TGT TTC CGA CCT CAC GGG GTC TCA GCA GCG CAA GAG AAA 192 Asp He Asn Cys Phe Arg Pro His Gly Val Ser Ala Ala Gin Glu Lys 50 55 60 ATT TCC TTC GGA AAG TCG TCC CAA TGT CGT GAA GCC GTC GGT ACT CCC 240 He Ser Phe Gly Lys Ser Ser Gin Cys Arg Glu Ala Val Gly Thr Pro 65 70 75 80 CAG TAC ATC ACG ATA ACG GCT AAC GTG ACC GAC GAA TCA TAC TTG TAC 28B Gin Tyr He Thr He Thr Ala Asn Val Thr Asp Glu Ser Tyr Leu Tyr 85 90 95 AAC GCG GAC CTG CTG ATG CTT TCT GCG TGC CTT TTC TAC GCC TCA GAA 336 Asn Ala Asp Leu Leu Met Leu Ser Ala Cys Leu Phe Tyr Ala Ser Glu 100 105 110 ATG AGC GAG AAA GGC TTC AAA GTC ATC TTT GGG AAT GTC TCT GGC GTT 384 Met Ser Glu Lys Gly Phe Lys Val He Phe Gly Asn Val Ser Gly Val 115 120 125 GTT TCT GCT TGT GTC AAT TTC ACA GAT TAT GTG GCC CAT GTG ACC CAA 432 Val Ser Ala Cys Val Asn Phe Thr Asp Tyr Val Ala His Val Thr Gin 130 135 140 CAT ACC CAG CAG CAT CAT CTG GTA ATT GAT CAC ATT CGG TTG CTG CAT 480 His Thr Gin Gin His His Leu Val He Asp His He Arg Leu Leu His 145 150 155 160 TTC CTG ACA CCA TCT GCA ATG AGG TGG GCT ACA ACC ATT GCT TGT TTG 528 Phe Leu Thr Pro Ser Ala Met Arg Trp Ala Thr Thr He Ala Cys Leu 165 170 175 TTC GCC ATT CTC TTG GCA ATA 549 Phe Ala He Leu Leu Ala He 180 (2) INFORMATION FOR SEQ ID NO:20: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 183 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:20: Met Ala Ala Ala Thr Leu Phe Phe Leu Ala Gly Ala Gin His He Met 1 5 10 15 Val Ser Glu Ala Phe Ala Cys Lys Pro Cys Phe Ser Thr His Leu Ser 20 25 30 Asp He Glu Thr Asn Thr Thr Ala Ala Ala Gly Phe Met Val Leu Gin 35 40 45 Asp He Asn Cys Phe Arg Pro His Gly Val Ser Ala Ala Gin Glu Lys 50 55 60 He Ser Phe Gly Lys Ser Ser Gin Cys Arg Glu Ala Val Gly Thr Pro 65 70 75 80 Gin Tyr He Thr He Thr Ala Asn Val Thr Asp Glu Ser Tyr Leu Tyr 85 90 95 Asn Ala Asp Leu Leu Met Leu Ser Ala Cys Leu Phe Tyr Ala Ser Glu 100 105 110 Met Ser Glu Lys Gly Phe Lys Val He Phe Gly Asn Val Ser Gly Val 115 120 125 Val Ser Ala Cys Val Asn Phe Thr Asp Tyr Val Ala His Val Thr Gin 130 135 140 His Thr Gin Gin His His Leu Val He Asp His He Arg Leu Leu His 145 150 155 160 Phe Leu Thr Pro Ser Ala Met Arg Trp Ala Thr Thr He Ala Cys Leu 165 170 175 Phe Ala He Leu Leu Ala He 180 (2) INFORMATION FOR SEQ ID NO:21: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 603 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 1..603 (D) OTHER INFORMATION: /standard name- "LV ORF 5" (xi) SEQUENCE DESCRIPTION: SEQ ID NO:21: ATG AGA TGT TCT CAC AAA TTG GGG CGT TTC TTG ACT CCG CAC TCT TGC 48 Met Arg Cys Ser His Lys Leu Gly Arg Phe Leu Thr Pro His Ser Cys 1 5 10 15 TTC TGG TGG CTT TTT TTG CTG TGT ACC GGC TTG TCC TGG TCC TTT GCC 96 Phe Trp Trp Leu Phe Leu Leu Cys Thr Gly Leu Ser Trp Ser Phe Ala 20 25 30 GAT GGC AAC GGC GAC AGC TCG ACA TAC CAA TAC ATA TAT AAC TTG ACG 144 Asp Gly Asn Gly Asp Ser Ser Thr Tyr Gin Tyr He Tyr Asn Leu Thr 35 40 45 ATA TGC GAG CTG AAT GGG ACC GAC TGG TTG TCC AGC CAT TTT GGT TGG 192 He Cys Glu Leu Asn Gly Thr Asp Trp Leu Ser Ser His Phe Gly Trp 50 55 60 GCA GTC GAG ACC TTT GTG CTT TAC CCG GTT GCC ACT CAT ATC CTC TCA 240 Ala Val Glu Thr Phe Val Leu Tyr Pro Val Ala Thr His He Leu Ser 65 70 75 80 CTG GGT TTT CTC ACA ACA AGC CAT TTT TTT GAC GCG CTC GGT CTC GGC 288 Leu Gly Phe Leu Thr Thr Ser His Phe Phe Asp Ala Leu Gly Leu Gly 85 90 95 GCT GTA TCC ACT GCA GGA TTT GTT GGC GGG CGG TAC GTA CTC TGC AGC 336 Ala Val Ser Thr Ala Gly Phe Val Gly Gly Arg Tyr Val Leu Cys Ser 100 105 110 GTC TAC GGC GCT TGT GCT TTC GCA GCG TTC GTA TGT TTT GTC ATC CGT 384 Val Tyr Gly Ala Cys Ala Phe Ala Ala Phe Val Cys Phe Val He Arg 115 120 125 GCT GCT AAA AAT TGC ATG GCC TGC CGC TAT GCC CGT ACC CGG TTT ACC 432 Ala Ala Lys Asn Cys Met Ala Cys Arg Tyr Ala Arg Thr Arg Phe Thr 130 135 140 AAC TTC ATT GTG GAC GAC CGG GGG AGA GTT CAT CGA TGG AAG TCT CCA 480 Asn Phe He Val Asp Asp Arg Gly Arg Val His Arg Trp Lys Ser Pro 145 150 155 160 ATA GTG GTA GAA AAA TTG GGC AAA GCC GAA GTC GAT GGC AAC CTC GTC 528 He Val Val Glu Lys Leu Gly Lys Ala Glu Val Asp Gly Asn Leu Val 165 170 175 ACC ATC AAA CAT GTC GTC CTC GAA GGG GTT AAA GCT CAA CCC TTG ACG 576 Thr He Lys His Val Val Leu Glu Gly Val Lys Ala Gin Pro Leu Thr 180 185 190 AGG ACT TCG GCT GAG CAA TGG GAG GCC 603 Arg Thr Ser Ala Glu Gin Trp Glu Ala 195 200 (2) INFORMATION FOR SEQ ID NO:22: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 201 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:22: Met Arg Cys Ser His Lys Leu Gly Arg Phe Leu Thr Pro His Ser Cys 1 5 10 15 Phe Trp Trp Leu Phe Leu Leu Cys Thr Gly Leu Ser Trp Ser Phe Ala 20 25 30 Asp Gly Asn Gly Asp Ser Ser Thr Tyr Gin Tyr He Tyr Asn Leu Thr 35 40 45 He Cys Glu Leu Asn Gly Thr Asp Trp Leu Ser Ser His Phe Gly Trp 50 55 60 Ala Val Glu Thr Phe Val Leu Tyr Pro Val Ala Thr His He Leu Ser 65 70 75 80 Leu Gly Phe Leu Thr Thr Ser His Phe Phe Asp Ala Leu Gly Leu Gly 85 90 95 Ala Val Ser Thr Ala Gly Phe Val Gly Gly Arg Tyr Val Leu Cys Ser 100 105 110 Val Tyr Gly Ala Cys Ala Phe Ala Ala Phe Val Cys Phe Val He Arg 115 120 125 Ala Ala Lys Asn Cys Met Ala Cys Arg Tyr Ala Arg Thr Arg Phe Thr 130 135 140 Asn Phe He Val Asp Asp Arg Gly Arg Val His Arg Trp Lys Ser Pro 145 150 155 160 He Val Val Glu Lys Leu Gly Lys Ala Glu Val Asp Gly Asn Leu Val 165 170 175 Thr He Lys His Val Val Leu Glu Gly Val Lys Ala Gin Pro Leu Thr 180 185 190 Arg Thr Ser Ala Glu Gin Trp Glu Ala 195 200 (2) INFORMATION FOR SEQ ID NO:23: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 519 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS : double (D) TOPOLOGY: unknown (ii) MOLECULE TYPE: cDNA (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 1..519 (D) OTHER INFORMATION: /standard name- "LV ORF 6" (xi) SEQUENCE DESCRIPTION: SEQ ID NO:23: ATG GGA GGC CTA GAC GAT TTT TGC AAC GAT CCT ATC GCC GCA CAA AAG 48 Met Gly Gly Leu Asp Asp Phe Cys Asn Asp Pro He Ala Ala Gin Lys 1 5 10 15 CTC GTG CTA GCC TTT AGC ATC ACA TAC ACA CCT ATA ATG ATA TAC GCC 96 Leu Val Leu Ala Phe Ser He Thr Tyr Thr Pro He Met He Tyr Ala 20 25 30 CTT AAG GTG TCA CGC GGC CGA CTC CTG GGG CTG TTG CAC ATC CTA ATA 144 Leu Lys Val Ser Arg Gly Arg Leu Leu Gly Leu' Leu His He Leu He 35 40 45 TTT CTG AAC TGT TCC TTT ACA TTC GGA TAC ATG ACA TAT GTG CAT TTT 192 Phe Leu Asn Cys Ser Phe Thr Phe Gly Tyr Met Thr Tyr Val His Phe 50 55 60 CAA TCC ACC AAC CGT GTC GCA CTT ACC CTG GGG GCT GTT GTC GCC CTT 240 Gin Ser Thr Asn Arg Val Ala Leu Thr Leu Gly Ala Val Val Ala Leu 65 70 75 80 CTG TGG GGT GTT TAC AGC TTC ACA GAG TCA TGG AAG TTT ATC ACT TCC 288 Leu Trp Gly Val Tyr Ser Phe Thr Glu Ser Trp Lys Phe He Thr Ser 85 90 95 AGA TGC AGA TTG TGT TGC CTT GGC CGG CGA TAC ATT CTG GCC CCT GCC 336 Arg Cys Arg Leu Cys Cys Leu Gly Arg Arg Tyr He Leu Ala Pro Ala 100 105 110 CAT CAC GTA GAA AGT GCT GCA GGT CTC CAT TCA ATC TCA GCG TCT GGT 384 His His Val Glu Ser Ala Ala Gly Leu His Ser He Ser Ala Ser Gly 115 120 125 AAC CGA GCA TAC GCT GTG AGA AAG CCC GGA CTA ACA TCA GTG AAC GGC 432 Asn Arg Ala Tyr Ala Val Arg Lys Pro Gly Leu Thr Ser Val Asn Gly 130 135 140 ACT CTA GTA CCA GGA CTT CGG AGC CTC GTG CTG GGC GGC AAA CGA GCT 480 Thr Leu Val Pro Gly Leu Arg Ser Leu Val Leu Gly Gly Lys Arg Ala 145 150 155 160 GTT AAA CGA GGA GTG GTT AAC CTC GTC AAG TAT GGC CGG 519 Val Lys Arg Gly Val Val Asn Leu Val Lys Tyr Gly Arg 165 170 (2) INFORMATION FOR SEQ ID NO:24: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 173 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:24: Met Gly Gly Leu Asp Asp Phe Cys Asn Asp Pro He Ala Ala Gin Lys 1 5 10 15 Leu Val Leu Ala Phe Ser He Thr Tyr Thr Pro He Met He Tyr Ala 20 25 30 Leu Lys Val Ser Arg Gly Arg Leu Leu Gly Leu Leu His He Leu He 35 40 45 Phe Leu Asn Cys Ser Phe Thr Phe Gly Tyr Met Thr Tyr Val His Phe 50 55 60 Gin Ser Thr Asn Arg Val Ala Leu Thr Leu Gly Ala Val Val Ala Leu 65 70 75 80 Leu Trp Gly Val Tyr Ser Phe Thr Glu Ser Trp Lys Phe He Thr Ser 85 90 95 Arg Cys Arg Leu Cys Cys Leu Gly Arg Arg Tyr He Leu Ala Pro Ala 100 105 110 His His Val Glu Ser Ala Ala Gly Leu His Ser He Ser Ala Ser Gly 115 120 125 Asn Arg Ala Tyr Ala Val Arg Lys Pro Gly Leu Thr Ser Val Asn Gly 130 135 140 Thr Leu Val Pro Gly Leu Arg Ser Leu Val Leu Gly Gly Lys Arg Ala 145 150 155 160 Val Lys Arg Gly Val Val Asn Leu Val Lys Tyr Gly Arg 165 170 (2) INFORMATION FOR SEQ ID NO:25: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 384 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS : double (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 1..384 (D) OTHER INFORMATION: /standard name- "LV ORF 7" (xi) SEQUENCE DESCRIPTION: SEQ ID NO:25: ATG GCC GGT AAA AAC CAG AGC CAG AAG AAA AAG AAA AGT ACA GCT CCG 48 Met Ala Gly Lys Asn Gin Ser Gin Lys Lys Lys Lys Ser Thr Ala Pro 1 5 10 - 15 ATG GGG AAT GGC CAG CCA GTC AAT CAA CTG TGC CAG TTG .CTG GGT GCA 96 Met Gly Asn Gly Gin Pro Val Asn Gin Leu Cys Gin Leu Leu Gly Ala 20 25 30 ATG ATA AAG TCC CAG CGC CAG CAA CCT AGG GGA GGA CAG GCC AAA AAG 144 Met He Lys Ser Gin Arg Gin Gin Pro Arg Gly Gly Gin Ala Lys Lys 35 40 45 AAA AAG CCT GAG AAG CCA CAT TTT CCC CTG GCT GCT GAA GAT GAC ATC 192 Lys Lys Pro Glu Lys Pro His Phe Pro Leu Ala Ala Glu Asp Asp He 50 55 60 CGG CAC CAC CTC ACC CAG ACT GAA CGC TCC CTC TGC TTG CAA TCG ATC 240 Arg His His Leu Thr Gin Thr Glu Arg Ser Leu Cys Leu Gin Ser He 65 70 75 80 CAG ACG GCT TTC AAT CAA GGC GCA GGA ACT GCG TCG CTT TCA TCC AGC 288 Gin Thr Ala Phe Asn Gin Gly Ala Gly Thr Ala Ser Leu Ser Ser Ser 85 90 95 GGG AAG GTC AGT TTT CAG GTT GAG TTT ATG CTG CCG GTT GCT CAT ACA 336 Gly Lys Val Ser Phe Gin Val Glu Phe Met Leu Pro Val Ala His Thr 100 105 110 GTG CGC CTG ATT CGC GTG ACT TCT ACA TCC GCC AGT CAG GGT GCA AGT 384 Val Arg Leu He Arg Val Thr Ser Thr Ser Ala Ser Gin Gly Ala Ser 115 120 125 (2) INFORMATION FOR SEQ ID NO:26: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 128 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein ( i) SEQUENCE DESCRIPTION: SEQ ID NO:26: Met Ala Gly Lys Asn Gin Ser Gin Lys Lys Lys Lys Ser Thr Ala Pro 1 5 10 15 Met Gly Asn Gly Gin Pro Val Asn Gin Leu Cys Gin Leu Leu Gly Ala 20 25 30 Met He Lys Ser Gin Arg Gin Gin Pro Arg Gly Gly Gin Ala Lys Lys 35 40 45 Lys Lys Pro Glu Lys Pro His Phe Pro Leu Ala Ala Glu Asp Asp He 50 55 60 Arg His His Leu Thr Gin Thr Glu Arg Ser Leu Cys Leu Gin Ser He 65 70 75 80 Gin Thr Ala Phe Asn Gin Gly Ala Gly Thr Ala Ser Leu Ser Ser Ser 85 90 95 Gly Lys Val Ser Phe Gin Val Glu Phe Met Leu Pro Val Ala His Thr 100 105 110 Val Arg Leu He Arg Val Thr Ser Thr Ser Ala Ser Gin Gly Ala Ser 115 120 125

Claims: Claims: 1. A purified and isolated nucleic acid comprising a fragmentary portion of the VR-2332 genome between ORF 2 and ORF 7 and having a length sufficient to provide a nucleotide sequence that is unique with respect to the LV virus genome. 2. The nucleic acid as set forth in Claim 1 , said portion including a coding region for the expression of a polypeptide capable of inducing an anti-PRRS immune response in swine. 3. The nucleic acid as set forth in Claim 1 , including said portion selected from Sequence ID No. 1 and being sufficiently dissimilar from portions of Sequence ID. No. 14 to prevent PCR amplification of portions of said Sequence ID No. 1. 4. The nucleic acid as set forth in Claim 3, including said portion consisting essentially of a sequence selected from a group consisting of Sequence ID Nos. 2, 4, 6, 8, 10, 12, and combinations thereof, together with all complimentary strands and degenerate amino acid residue coding equivalencies that may be obtained by site-directed mutagenesis. 5. The nucleic acid as set forth in Claim 3, including said portion consisting essentially of a sequence selected from a group consisting of Sequence ID Nos. 2, 4, 6, 8, 10, and 12, as well as inverse complimentary sequences depending from Sequence ID Nos. 2, 4, 6, 8, 10, and 12. 6. The nucleic acid as set forth in Claim 5, said group consisting of Sequence ID No. 1 from positions 2783 to 2801 , the inverse compliment of Sequence ID No. 1 from positions 3271 to 3289, Sequence ID No. 1 from positions 2289 to 2307, the inverse compliment of Sequence ID No. 1 from positions 2862 to 2880, Sequence ID No. 14 from positions 14112 to 14131, the inverse compliment of Sequence ID No. 14 from positions 14551 to 14570, Sequence ID No, 14 from positions 14575 to 14594, and the inverse compliment of Sequence ID NO. 14 from positions 14955 to 14974, sequence ID No. 1 from positions 2814 to 2832, the inverse compliment of Sequence ID No. 1 from positions 3273 to 3291 , Sequence ID No. 1 from positions 2816 to 2834, and the inverse compliment of Sequence ID No. 1 from positions 3181 to 3198. 7. A chimeric vector for use in expressing viral proteins from a host cell, comprising a promoter and a termination sequence connected by a coding region insert including a fragmentary portion of the VR-2332 genome between ORF 2 and ORF 7, said insert having a length sufficient to provide a nucleotide sequence unique with respect to the LV virus genome, together with all degenerate amino acid residue coding equivalencies that may be obtained by site-directed mutagenesis. 8. The vector as set forth in Claim 7, including said insert consisting essentially of a sequence selected from a group consisting of Sequence ID Nos. 2, 4, 6, 8, 10, and 12, as well as inverse complimentary sequences depending from Sequence ID Nos. 2, 4, 6, 8, 10, and 12. 9. A vaccine for immunizing animals against a VR-2332 form of PRRS, comprising a polypeptide-coding region replicating a nucleotide sequence selected as a portion of Sequence ID No. 1 and having a length sufficient to provide a nucleotide sequence unique in comparison with respect to Sequence ID No. 14. 10. The vaccine as set forth in Claim 9, said coding region consisting essentially of a member selected from the group consisting of Sequence ID Nos. 2, 4, 6, 8, 10, and 12, and combinations thereof. 11. A vaccine for immunizing animals against a VR-2332 form of PRRS, comprising a VR-2332 amino acid residue sequence having a length sufficient to provide uniqueness in comparison with respect to LV virus amino acid residue sequences. 12. The vaccine as set forth in Claim 11 , said VR-2332 amino acid residue sequence consisting essentially of a sequence selected from the group consisting of Sequence ID Nos. 3, 5, 7, 9, 11, and 13, and combinations thereof. 13. A diagnostic assay for distinguishing between PRRS- causative viral strains, said assay comprising the steps of. providing PCR oligonucleotide primers capable of selectively amplifying fragmentary genomic portions of a wild-type PRRS-causative virus; obtaining a sample including cDNA derived from swine exhibiting PRRS clinical signs; and using said primers in a polymerase chain reaction under conditions capable of selective amplification of cDNA from said PRRS- causative virus in said sample. 14. The assay as set forth in Claim 13, said PRRS-causative virus being selected from a group consisting of VR-2332 and LV virus. 15. The assay as set forth in Claim 14 including said primers being selected from a group consisting of fragmentary portions of Sequence ID No. 1, complimentary fragments of Sequence ID No. 1, fragmentary portions of Sequence ID No. 14, and complimentary fragments of Sequence ID No. 14, said primers being unique in comparison with respect to Sequence ID No. 14 when said primers derive from Sequence ID No. 1, said primers being unique in comparison with respect to Sequence ID No. 1 when said primers derive from Sequence ID No. 14; 16. A method of vaccinating an animal against VR-2332- caused PRRS, said method comprising the steps of: providing a vaccine including at least one material selected from a group consisting of VR-2332 based polypeptides and VR-2332 based nucleic acids; and administering said vaccine to said animal in a manner permitting said animal to develop an immune response to said material.

Inventors: ELAM MARGARET R, KAKACH LAURA T, MURTAUGH MICHAEL P, ELAM, MARGARET, R., KAKACH, LAURA, T., MURTAUGH, MICHAEL, P.
Applicants: UNIV MINNESOTA, REGENTS OF THE UNIVERSITY OF MINNESOTA
Application year: 1995
Main classification: A61K39
IPC codes: A61K38, A61K39, A61P31, C07H21, C07K14, C12N15, G01N33